Skip to Content

Jaffer A. Ajani, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1971 Government Medical College, Nagpur, India, MD

Postgraduate Training

7/1981-6/1982 Research Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1980-6/1981 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1978-6/1980 Clinical Residency, Internal Medicine, Tulane University School of Medicine, New Orleans, LA
7/1977-6/1978 Clinical Internship, Internal Medicine, Tulane University School of Medicine, New Orleans, LA
7/1975-6/1977 Clinical Residency, Family Practice, Altoona General Hospital, Pennsylvania State University, Altoona, PA
7/1974-6/1975 Clinical Internship, Family Practice, Altoona General Hospital, Pennsylvania State University, Altoona, PA
1/1973-5/1974 Clinical Residency, General Surgery and Orthopedics, Government Medical College, Nagpur, India
1/1972-12/1972 Clinical Internship, Government Medical College, Nagpur, India

Board Certifications

1/1983 Internal Medicine-Medical Oncology
1/1979 Internal Medicine
1/1977 Family Practice

Honors and Awards

1998 Cited in Good Housekeeping Magazine as Best Doctors in America for Colorectal Carcinoma, Good Housekeeping Magazine
1996 Cited in Best Doctors in America (Central Division), Woodward/White Publishers, Inc.
1992 Cited in Good Housekeeping Magazine (October 1992) as one of the Best Cancer Doctors in America, Good Housekeeping Magazine
1981 Fellowship Award for Excellence in Clinical Oncology, U. T. M. D. Anderson Cancer Center, Houston, TX

Selected Publications

Peer-Reviewed Original Research Articles

1. Wu Y, Grabsch H, Ivanova T, Tan IB, Murray J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, Lee M, Lee J, Koo JH, Yeoh KG, van Grieken N, Ylstra B, Rha SY, Ajani JA, Cheong JH, Noh SH, Lim KH, Boussioutas A, Lee JS, Tan P. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut 62(8):1100-11, 8/2013. e-Pub 6/26/2012. PMID: 22735568.
2. Pan JY, Ajani JA, Gu J, Gong Y, Quin A, Hung M, Wu X, Izzo JG. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer 118(17):4346-53, 9/1/2012. e-Pub 12/27/2011. PMID: 22213102.
3. Blum MA, Ajani JA. Chemoradiation: Gastro-oesophageal cancer-is CROSSing over so hard to do? Nat Rev Clin Oncol 9(9):493-4, 8/2012. e-Pub 7/2012. PMID: 22825372.
4. Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 83(3):e345-51, 7/1/2012. e-Pub 3/13/2012. PMID: 22417808.
5. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection. J Clin Oncol 30(19):2327-33, 7/1/2012. e-Pub 5/14/2012. PMID: 22585691.
6. Jiang Y, Ajani JA. Anal margin cancer: current situation and ongoing trials. Curr Opin Oncol 24(4):448-53, 7/2012. PMID: 22581355.
7. Amini A, Xiao L, Allen PK, Suzuki A, Hayashi Y, Liao Z, Hofstetter W, Crane C, Komaki R, Bhutani MS, Lee JH, Ajani JA, Welsh J. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys 83(2):e231-9, 6/1/2012. e-Pub 3/19/2012. PMID: 22436793.
8. Chakravarty T, Crane CH, Ajani JA, Mansfield PF, Briere TM, Beddar AS, Mok H, Reed VK, Krishnan S, Delclos ME, Das P. Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy as Preoperative Treatment for Localized Gastric Adenocarcinoma. Int J Radiat Oncol Biol Phys 83(2):581-6, 6/1/2012. e-Pub 12/2/2011. PMID: 22137021.
9. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 118(10):2632-40, 5/15/2012. e-Pub 10/5/2011. PMID: 22565611.
10. Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A Phase II Study of a Paclitaxel-based Chemoradiation Regimen with Selective Surgical Salvage for Resectable Locoregionally Advanced Esophageal Cancer: Initial Reporting of RTOG 0246. Int J Radiat Oncol Biol Phys 82(5):1967-72, 4/1/2012. e-Pub 4/18/2011. PMID: 21507583.
11. Blum MA, Ajani JA. Therapy: Localized gastric cancer-a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol 9(4):194-5, 4/2012. e-Pub 3/6/2012. PMID: 22392288.
12. Ajani JA, Blum MA, Estrella JS, Das P, Fournier KF. Gastric Cancer: Apples Will Always Be Apples. J Clin Oncol 30(9):1017-8; author reply 1019-20, 3/20/2012. e-Pub 2/13/2012. PMID: 22331947.
13. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 21(3):374-87, 3/20/2012. PMCID: PMC3350095.
14. Kountourakis P, Ajani JA, Davila M, Lee JH, Bhutani MS, Izzo JG. Barrett's Esophagus: A Review of Biology and Therapeutic Approaches. Gastrointest Cancer Res 5(2):49-57, 3/2012. PMCID: PMC3369601.
15. Thosani N, Singh H, Kapadia A, Ochi N, Lee JH, Ajani J, Swisher SG, Hofstetter WL, Guha S, Bhutani MS. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc 75(2):242-53, 2/2012. e-Pub 11/23/2011. PMID: 22115605.
16. Harvin JA, Lahat G, Correa AM, Lee J, Maru D, Ajani J, Marom EM, Welsh J, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: Significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg 143(2):412-20, 2/2012. e-Pub 12/14/2011. PMID: 22172216.
17. Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal Cancer Dose Escalation using a Simultaneous Integrated Boost Technique. Int J Radiat Oncol Biol Phys 82(1):468-74, 1/1/2012. e-Pub 12/1/2010. PMID: 21123005.
18. Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, Ajani JA, Maru DM, Bhutani MS, Welsh J, Marom EM, Swisher SG, Hofstetter WL. Does the Timing of Esophagectomy After Chemoradiation Affect Outcome? Ann Thorac Surg 93(1):207-13, 1/2012. e-Pub 10/1/2011. PMID: 21962263.
19. Ajani JA, Swisher SG. Preoperative Chemotherapy for Localized Squamous Cell Carcinoma of the Esophagus? We Should Go Back to the Drawing Board! Ann Surg Oncol 19(1):3-4, 1/2012. e-Pub 10/2011. PMID: 21989665.
20. Hayashi Y, Blum MA, Ajani JA. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. Onkologie 35(4):204-9, 2012. e-Pub 3/15/2012. PMID: 22488092.
21. Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, Ajani JA. Localized Gastric Cancer Treated with Chemoradation without Surgery: UTMD Anderson Cancer Center Experience. Oncology 82(6):347-351, 2012. e-Pub 6/2/2012. PMID: 22677933.
22. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for Prognostication of Outcome in Patients with Esophageal and Gastroesophageal Carcinoma Undergoing Definitive Chemoradiotherapy. Oncology 82(2):108-113, 2012. PMID: 22328056.
23. Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, Ajani JA, Cox JD. Intensity-Modulated Proton Therapy Further Reduces Normal Tissue Exposure During Definitive Therapy for Locally Advanced Distal Esophageal Tumors: A Dosimetric Study. Int J Radiat Oncol Biol Phys 81(5):1336-42, 12/1/2011. e-Pub 4/4/2011. PMID: 21470796.
24. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB. Dual inhibition of Tumor Energy Pathway by 2-deoxy glucose and metformin Is Effective Against a Broad Spectrum of Preclinical Cancer Models. Mol Cancer Ther 10(12):2350-62, 12/2011. e-Pub 10/12/2011. PMCID: PMC3237863.
25. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4823-33, 11/1/2011. e-Pub 3/31/2011. PMCID: PMC3144261.
26. Ajani JA, Mangu PB, Burstein HJ. Peek before you treat? Is it a fantasy or reality? J Oncol Pract 7(5):338-9, 9/2011. PMCID: PMC3170070.
27. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D, Ajani JA, American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays. J Clin Oncol 29(24):3328-30, 8/20/2011. e-Pub 7/25/2011. PMID: 21788567.
28. Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw 9(8):830-87, 8/1/2011. PMID: 21900218.
29. Glasgow RE, Ilson DH, Hayman JA, Gerdes H, Mulcahy MF, Ajani JA. Modern approaches to localized cancer of the esophagus. J Natl Compr Canc Netw 9(8):902-11, 8/1/2011. PMID: 21900220.
30. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P. Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Gastroenterology 141(2):476-485.e11, 8/2011. e-Pub 4/28/2011. PMCID: PMC3152688.
31. Estrella JS, Hofstetter WL, Correa AM, Swisher SG, Ajani JA, Lee JH, Bhutani MS, Abraham SC, Rashid A, Maru DM. Duplicated Muscularis Mucosae Invasion has Similar Risk of Lymph Node Metastasis and Recurrence-free Survival as Intramucosal Esophageal Adenocarcinoma. Am J Surg Pathol 35(7):1045-53, 7/2011. e-Pub 5/2011. PMID: 21602659.
32. Blum M, Suzuki A, Ajani JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol 7(6):715-26, 6/2011. PMID: 21675835.
33. Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep 13(3):157-67, 6/2011. PMID: 21365188.
34. Khokhar NZ, Jiang Y, Benson AB, Ajani JA, Mulcahy MF. Refining docetaxel-containing therapy for gastric cancer. Gastrointest Cancer Res 4(3):96-105, 5/2011. PMCID: PMC3201643.
35. Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, Kim SB, Kim H, Hong SW, Park YN, Noh SH, Park ES, Chu IS, Hong WK, Ajani JA, Lee JS. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 17(7):1850-7, 4/1/2011. e-Pub 3/29/2011. PMCID: PMC3078023.
36. Kountourakis P, Correa AM, Hofstetter WL, Lee JH, Bhutani MS, Rice DC, Komaki R, Maru DM, Ross WA, Vaporciyan A, Swisher SG, Ajani JA. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer 117(5):925-30, 3/1/2011. e-Pub 10/19/2010. PMCID: PMC3080168.
37. Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, Ajani JA, Xu XC. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer 128(1):132-43, 1/1/2011. e-Pub 3/2010. PMCID: PMC2937084.
38. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C. Impact of Overall Treatment Time on Survival and Local Control in Patients With Anal Cancer: A Pooled Data Analysis of Radiation Therapy Oncology Group Trials 87-04 and 98-11. J Clin Oncol 28(34):5061-6, 12/1/2010. e-Pub 10/18/2010. PMCID: PMC3018356.
39. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Lee JH, Bhutani MS, Dekovich A, Swisher SG, Ajani JA. The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer 116(24):5619-27, 12/2010. PMID: 21136578.
40. Jiang Y, Ajani JA. Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol 26(6):640-6, 11/2010. PMID: 20827183.
41. Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer 116(19):4487-94, 10/2010. PMID: 20629031.
42. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila) 3(9):1176-86, 9/2010. e-Pub 7/22/2010. PMID: 20651033.
43. Swisher SG, Hofstetter W, Komaki R, Correa AM, Erasmus J, Lee JH, Liao Z, Maru D, Mehran R, Patel S, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Ajani JA. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg 90(3):892-8; discussion 898-9, 9/2010. PMID: 20732514.
44. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg 90(3):884-90; discussion 890-1, 9/2010. PMID: 20732513.
45. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer 116(17):4007-13, 9/2010. PMID: 20564111.
46. Jiang Y, Mackley H, Cheng H, Ajani JA. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomark Med 4(4):535-41, 8/2010. PMID: 20701442.
47. Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer 116(11):2511-8, 6/1/2010. PMID: 20301114.
48. Shah MA, Ajani JA. Gastric cancer--an enigmatic and heterogeneous disease. JAMA 303(17):1753-4, 5/5/2010. PMID: 20442394.
49. Ajani JA. Resectable Esophageal Cancer: Surgery As Primary Therapy Is Not the Answer, but Then, What Is and Why? J Clin Oncol 28(15):e243-4, 5/20/2010. e-Pub 4/5/2010. PMID: 20368554.
50. Zachariah B, Gwede CK, James J, Ajani J, Chin LJ, Donath D, Rosenthal SA, Kane BL, Rotman M, Berk L, Kachnic LA. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. J Natl Cancer Inst 102(8):547-56, 4/21/2010. e-Pub 3/25/2010. PMCID: PMC2857801.
51. Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer 116(7):1656-63, 4/1/2010. e-Pub 2/2010. PMID: 20143431.
52. Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A. Molecular Biomarkers Correlate with Disease-Free Survival in Patients with Anal Canal Carcinoma Treated with Chemoradiation. Dig Dis Sci 55(4):1098-105, 4/2010. e-Pub 4/28/2009. PMID: 19399614.
53. Das P, Jiang Y, Lee JH, Bhutani MS, Ross WA, Mansfield PF, Ajani JA. Multimodality approaches to localized gastric cancer. J Natl Compr Canc Netw 8(4):417-25, 4/2010. PMID: 20410334.
54. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial. J Clin Oncol 28(9):1547-53, 3/20/2010. e-Pub 2/16/2010. PMID: 20159816.
55. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. e-Pub 1/27/2010. PMID: 20108336.
56. Jiang Y, Mackley H, Cheng H, Ajani JA. Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy? J Natl Compr Canc Netw 8(1):135-44, 1/2010. PMID: 20064295.
57. Correa MC, Deus HF, Vasconcelos AT, Hayashi Y, Ajani JA, Patnana SV, Almeida JS. AGUIA: autonomous graphical user interface assembly for clinical trials semantic data services. BMC Med Inform Decis Mak 10:65, 2010. e-Pub 10/26/2010. PMCID: PMC2987967.
58. Ajani JA. In the ring with a raging bull: unresectable localized esophageal carcinoma. Onkologie 33(5):220-1, 2010. e-Pub 4/20/2010. PMID: 20502055.
59. Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, Wu X, Coombes KR, Maru D, Wang KK, Buttar NS, Ajani JA, Lee JS. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 5(11):e15074, 2010. e-Pub 11/30/2010. PMCID: PMC2994829.
60. Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology 78(5-6):316-22, 2010. e-Pub 8/11/2010. PMID: 20699623.
61. Goodarzi M, Correa AM, Ajani JA, Swisher SG, Hofstetter WL, Guha S, Deavers MT, Rashid A, Maru DM. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Mod Pathol 22(12):1612-21, 12/2009. PMID: 19734842.
62. Braiteh F, Correa AM, Hofstetter WL, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Mehran RJ, Swisher SG, Ajani JA. Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy. Cancer 115(19):4450-8, 10/2009. PMID: 19562780.
63. Bolton WD, Hofstetter WL, Francis AM, Correa AM, Ajani JA, Bhutani MS, Erasmus J, Komaki R, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg 138(4):831-6, 10/2009. PMID: 19660349.
64. Al-Batran SE, Ajani JA. Accomplishments in 2008 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res 3(5 Supplement 2):S58-61, 9/2009.
65. Ajani JA. Accomplishments in gastrointestinal oncology in 2008: conclusion. Gastrointest Cancer Res 3(5 Supplement 2):S79, 9/2009. PMCID: PMC2791378.
66. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 15(18):5744-52, 9/2009. PMCID: PMC2745487.
67. Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer, 8/14/2009. e-Pub 8/14/2009. PMID: 19685531.
68. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer 115(16):3609-17, 8/2009. PMID: 19526592.
69. Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with Esophageal Cancer Radiation Therapy. J Thorac Oncol 4(7):880-8, 7/2009. e-Pub 5/2009. PMID: 19458557.
70. Ajani JA. Chemotherapy and radiation resistance: version 2.0. J Clin Oncol 27(16):2735-6; author reply 2737-8, 6/2009. PMID: 19398570.
71. McCurdy M, McAleer MF, Wei W, Ezhil M, Johnson V, Khan M, Baker J, Luo D, Ajani J, Guerrero T. Induction and Concurrent Taxanes Enhance both the Pulmonary Metabolic Radiation Response and the Radiation Pneumonitis Response in Patients with Esophagus Cancer. Int J Radiat Oncol Biol Phys. e-Pub 6/2009. PMID: 19525073.
72. Guan X, Zhao H, Niu J, Tan D, Ajani JA, Wei Q. Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer. J Exp Clin Cancer Res 28:94, 6/2009. PMID: 19566948.
73. Xing J, Ajani JA, Chen M, Izzo J, Lin J, Chen Z, Gu J, Wu X. Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. Cancer Prev Res (Phila Pa) 2(5):459-65, 5/2009. PMID: 19401529.
74. Lagaly R, Horak A, Lee JH, Mansfield PF, Ajani JA. Patient with advanced gastric cancer responds twice to the same systemic therapy. Gastrointest Cancer Res. 3(3):115-7, 5/2009.
75. Maru DM, Luthra R, Correa AM, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Swisher SG, Ajani JA, Hofstetter WL, Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer 115(7):1576-85, 4/2009. e-Pub 1/2009. PMID: 19156915.
76. Pan J, Lin J, Izzo JG, Liu Y, Xing J, Huang M, Ajani JA, Wu X. Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis 30(5). e-Pub 3/6/2009. PMCID: PMC2675653.
77. Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, Hofstetter WL, Ajani JA, McAleer MF, Komaki R, Cox JD. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys 74(2). e-Pub 3/14/2009. PMID: 19289262.
78. Ajani JA. Future developments in esophageal cancer research. Gastroenterol Clin North Am 38(1):183-8, x, 3/2009. PMID: 19327575.
79. Jiang Y, Kimchi E, Ajani JA. Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach? Future Oncol 5(2):157-61, 3/2009. PMID: 19284374.
80. Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs 13(1). e-Pub 2/7/2009. PMID: 19201649.
81. Yendamuri S, Swisher SG, Correa AM, Hofstetter W, Ajani JA, Francis A, Maru D, Mehran RJ, Rice DC, Roth JA, Walsh GL, Vaporciyan AA. Esophageal tumor length is independently associated with long-term survival. Cancer 115(3):508-16, 2/1/2009. PMID: 19117343.
82. Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, Ajani JA. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer 115(3):624-30, 2/1/2009. PMID: 19130466.
83. Brücher BL, Swisher SG, Königsrainer A, Zieker D, Hartmann J, Stein H, Kitagawa Y, Law S, Ajani JA. Response to Preoperative Therapy in Upper Gastrointestinal Cancers. Ann Surg Oncol. e-Pub 2/5/2009. PMID: 19194759.
84. Chen G, Izzo J, Demizu Y, Wang F, Guha S, Wu X, Hung MC, Ajani J, Huang P. Different redox states in malignant and non-malignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol. Antioxid Redox Signal. e-Pub 1/12/2009. PMID: 19187006.
85. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy. J Clin Oncol. e-Pub 1/21/2009. PMID: 19164214.
86. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. US Intergroup Anal Carcinoma Trial: Tumor Diameter Predicts for Colostomy. J Clin Oncol. e-Pub 1/12/2009. PMID: 19139424.
87. Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating Quality in Clinical Cancer Research: The M.D. Anderson Cancer Center Experience. Oncology 77(2):75-81, 2009. PMID: 19571599.
88. Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol 9:77, 2009. PMCID: PMC2771032.
89. Izzo JG, Wu X, Wu TT, Huang P, Lee JS, Liao Z, Lee JH, Bhutani MS, Hofstetter W, Maru D, Hung MC, Ajani JA. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus 22(2):127-32, 2009. PMID: 19021681.
90. Ajani JA, Izzo JG, Lee JS. Chemotherapy and Radiotherapy Resistance: Complexity, Reality, and Promise. J Clin Oncol. e-Pub 12/2008. PMID: 19047300.
91. Cen P, Correa AM, Le JH, Maru D, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA, Vaporciyan A, Ajani JA. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus. e-Pub 11/2008. PMID: 19021684.
92. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113(8):2038-45, 10/2008. PMID: 18759326.
93. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Ilson DH, Kleinberg LR, McAleer MF, Meropol NJ, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Swisher SG, Washington MK, Willett C, Wood DE, Wright CD, Yang G, Yang G. Esophageal cancer. J Natl Compr Canc Netw 6(9):818-49, 10/2008. PMID: 18926093.
94. Ajani JA. Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw 6(9):813-4, 10/2008. PMID: 18998257.
95. Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG. Phase II Randomized Trial of Two Nonoperative Regimens of Induction Chemotherapy Followed by Chemoradiation in Patients With Localized Carcinoma of the Esophagus: RTOG 0113. J Clin Oncol 26(28):4551-6, 10/2008. e-Pub 6/2008. PMID: 18574157.
96. Ajani JA. Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation. Br J Cancer 99(7). e-Pub 9/2008. PMID: 18766183.
97. Ajani JA. Are capecitabine and oxaliplatin as effective as fluorouracil and cisplatin for gastroesophageal cancer? Nat Clin Pract Gastroenterol Hepatol 5(8):414-5, 8/2008. PMID: 18560397.
98. Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs 12(3):253-68, 7/2008. PMID: 18501674.
99. Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer, 7/2008. PMID: 18623381.
100. Ajani JA. Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer? Nat Clin Pract Oncol, 7/2008. PMID: 18628737.
101. Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer, 7/2008. PMID: 18623382.
102. Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, Komaki R, Ajani JA, Swisher SG, Hofstetter WL. Retrospective Study of Clinicopathologic Features and Prognosis of High-grade Neuroendocrine Carcinoma of the Esophagus. Am J Surg Pathol, 7/2008. PMID: 18670347.
103. Ajani J. Therapy of localized esophageal cancer: it is time to reengineer our investigative strategies. Onkologie 31(7):360-1, 7/2008. PMID: 18596381.
104. Jiang Y, Kimchi ET, Montero AJ, Staveley-O'Carroll KF, Ajani JA. Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther 8(6):975-91, 6/2008. PMID: 18533807.
105. Ajani JA, Schmoll HJ. Accomplishments in 2007 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res. 2(3 Suppl):S47-50, 5/2008.
106. Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys 71(1):167-72, 5/2008. PMID: 18406886.
107. Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, Ajani JA. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus, 5/2008. PMID: 18459989.
108. Scott LC, Yao JC, Benson AB, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol, 4/2008. PMID: 18398613.
109. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299(16):1914-21, 4/2008. PMID: 18430910.
110. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu C, Ajani JA, Phan A, Swisher SG, Mohan R, Cox JD, Komaki R. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol 3(3):277-82, 3/2008. PMID: 18317071.
111. Tetzlaff ED, Cen P, Ajani JA. Emerging drugs in the treatment of advanced gastric cancer. Expert Opin Emerg Drugs 13(1):135-44, 3/2008. PMID: 18321153.
112. Cen P, Hofstetter WL, Correa AM, Wu TT, Lee JH, Ross WA, Davilla M, Swisher SG, Fukami N, Rashid A, Maru D, Ajani JA. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer 112(5):1020-7, 3/2008. PMID: 18205187.
113. Baker J, Ajani JA. Proactive nurse management guidelines for managing intensive chemotherapy regimens in patients with advanced gastric cancer. Eur J Oncol Nurs, 3/2008. PMID: 18329956.
114. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316-23, 3/2008. PMID: 18323556.
115. Cen P, Hofstetter WL, Lee JH, Ross WA, Wu TT, Swisher SG, Davila M, Rashid A, Correa AM, Ajani JA. Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma. Cancer 112(3):503-10, 2/2008. PMID: 18072264.
116. Ajani JA. Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge! Ann Surg Oncol 14(12):3290-2, 12/2007. PMID: 17932722.
117. Reed VK, Krishnan S, Mansfield PF, Bhosale PR, Kim M, Das P, Janjan NA, Delclos ME, Lowy AM, Feig BW, Pisters PW, Ajani JA, Crane CH. Incidence, Natural History, and Patterns of Locoregional Recurrence in Gastric Cancer Patients Treated with Preoperative Chemoradiotherapy. Int J Radiat Oncol Biol Phys, 12/2007. PMID: 18164837.
118. Ajani JA. The area between the curves gets no respect: is it because of the median madness? J Clin Oncol 25(34):5531, 12/2007. PMID: 18048834.
119. Abraham SC, Krasinskas AM, Correa AM, Hofstetter WL, Ajani JA, Swisher SG, Wu TT. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol 31(11):1719-25, 11/2007. PMID: 18059229.
120. Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, Ajani JA. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer 110(10):2186-90, 11/2007. PMID: 17896785.
121. Cen P, Ajani JA. Medical treatment for advanced gastroesophageal adenocarcinoma. Curr Opin Gastroenterol 23(6):631-5, 11/2007. PMID: 17906439.
122. Izzo JG, Ajani JA. Thinking in and out of the box when it comes to gastric cancer and cyclooxygenase-2. J Clin Oncol 25(31):4865-7, 11/2007. PMID: 17971580.
123. Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol:1-7, 9/2007. PMID: 17899453.
124. Patel PR, Mansfield PF, Crane CH, Wu TT, Lee JH, Lynch PM, Morris J, Pisters PW, Feig B, Sunder PK, Izzo JG, Ajani JA. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer 110(5):989-95, 9/2007. PMID: 17636525.
125. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E, Van Cutsem E. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25(22):3205-9, 8/2007. PMID: 17664467.
126. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG, Willett CG, Willett CG. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25(24):3719-25, 8/2007. PMID: 17704421.
127. Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, Liao Z, Maru D, Wu TT, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Francis A, Blackmon S, Swisher SG. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg 84(2):365-73; discussion 374-5, 8/2007. PMID: 17643602.
128. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E, Van Cutsem E. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 25(22):3210-6, 8/2007. PMID: 17664468.
129. Das P, Crane CH, Ajani JA. Current treatment for localized anal carcinoma. Curr Opin Oncol 19(4):396-400, 7/2007. PMID: 17545807.
130. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 68(3):794-800, 7/2007. PMID: 17379452.
131. Izzo JG, Malhotra U, Wu TT, Luthra R, Correa AM, Swisher SG, Hofstetter W, Chao KS, Hung MC, Ajani JA. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev 16(6):1200-5, 6/2007. PMID: 17548685.
132. Tetzlaff ED, Correa AM, Baker J, Ensor J, Ajani JA. The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer 109(10):1989-95, 5/2007. PMID: 17397035.
133. Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. Ann Surg Oncol, 3/2007. PMID: 17342569.
134. Ajani JA. New proposal for postsurgery pathologic staging of esophageal or gastroesophageal junction adenocarcinoma: why bother? J Clin Oncol 25(7):906-7; author reply 908-9, 3/2007. PMID: 17327615.
135. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene, 3/2007. PMID: 17353904.
136. Izzo JG, Wu TT, Wu X, Ensor J, Luthra R, Pan J, Correa A, Swisher SG, Chao CK, Hittelman WN, Ajani JA. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol 25:698-707, 2/2007. PMID: 17308274.
137. Luthra MG, Ajani JA, Izzo J, Ensor J, Wu TT, Rashid A, Zhang L, Phan A, Fukami N, Luthra R. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res 13:912-9, 2/2007. PMID: 17289885.
138. Wang KL, Wu TT, Choi IS, Wang H, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109:658-67, 2/2007. PMID: 17211865.
139. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 13:234-40, 1/2007. PMID: 17200360.
140. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 109:125-34, 1/2007. PMID: 17146785.
141. Ross WA, Alkassab F, Lynch PM, Ayers GD, Ajani J, Lee JH, Bismar M. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointest Endosc 65:70-6, 1/2007. PMID: 17185082.
142. Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, Correa AM, Hofstetter WL, Ajani JA, Swisher SG. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol 31:58-64, 1/2007. PMID: 17197919.
143. Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB, 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 109:33-40, 1/2007. PMID: 17133415.
144. Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. Ann Surg Oncol, 1/2007. PMID: 17253104.
145. Luthra R, Luthra MG, Izzo J, Wu TT, Lopez-Alvarez E, Malhotra U, Choi IS, Zhang L, Ajani JA. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol 33 Suppl 11:2-5, 12/2006. PMID: 17178277.
146. Shao L, Hittelman WN, Lin J, Yang H, Ajani JA, Wu X. Deficiency of cell cycle checkpoints and DNA repair system predispose individuals to esophageal cancer. Mutat Res 602:143-50, 12/2006. PMID: 17011594.
147. Ajani JA. Introduction. Semin Oncol 33 Suppl 11:1, 12/2006. PMID: 17178276.
148. Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, Ajani JA. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer 107:2576-80, 12/2006. PMID: 17075877.
149. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R, Liao Z, Komaki R, van der Kogel A, Ajani J, Chao KS. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 12:6565-72, 11/2006. PMID: 17085672.
150. Kanai M, Wei D, Li Q, Jia Z, Ajani J, Le X, Yao J, Xie K. Loss of Kruppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res 12:6395-402, 11/2006. PMID: 17085651.
151. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-7, 11/2006. PMID: 17075117.
152. Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 5:2844-50, 11/2006. PMID: 17121931.
153. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 107:1475-82, 10/2006. PMID: 16944539.
154. Ajani JA, Safran H, Bokemeyer C, Shah MA, Lenz HJ, Van Cutsem E, Burris HA, 3rd, Lebwohl D, Mullaney B. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs 24(5):441-6, 9/2006. PMID: 16586011.
155. Wang SL, Liao Z, Liu H, Ajani J, Swisher S, Cox JD, Komaki R. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol 12:5501-8, 9/2006. PMID: 17006988.
156. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Wu TT, Swisher SG. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer 107(5):967-74, 9/2006. PMID: 16874819.
157. Wang KL, Yang Q, Cleary KR, Swisher SG, Correa AM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. Cancer, 9/2006. PMID: 16955509.
158. Ajani JA. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert Opin Pharmacother 7(12):1627-31, 8/2006. PMID: 16872265.
159. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, Ajani JA. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 107:676-85, 8/2006. PMID: 16847885.
160. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG, Chao KS. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 12(15):4590-7, 8/2006. PMID: 16899606.
161. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res 12(15):4598-604, 8/2006. PMID: 16899607.
162. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24(23):3789-98, 8/2006. PMID: 16785472.
163. Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J. Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 95:450-6, 8/2006. PMID: 16880795.
164. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 24(24):3953-8, 8/2006. PMID: 16921048.
165. Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs 24:353-7, 7/2006. PMID: 16683077.
166. Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107:221-31, 7/2006. PMID: 16770784.
167. Ajani JA. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho 33 Suppl 1:117-20, 6/2006. PMID: 16897985.
168. Ajani JA, Randolph Hecht J, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer 106(9):1908-16, 5/2006. PMID: 16568451.
169. Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs, 4/2006. PMID: 16628396.
170. Das P, Fukami N, Ajani JA. Combined modality therapy of localized gastric and esophageal cancers. J Natl Compr Canc Netw 4(4):375-82, 4/2006. PMID: 16569390.
171. Yasui W, Ajani JA, Nishiyama M, Ohtsu A, Tahara E. Current progress of cancer chemotherapy The Fifteenth International Symposium of the Hiroshima Cancer Seminar, October 2005. Cancer Sci 97(4):328-31, 4/2006. PMID: 16630126.
172. Wang SL, Liao Z, Vaporciyan AA, Tucker SL, Liu H, Wei X, Swisher S, Ajani JA, Cox JD, Komaki R. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 64(3):692-9, 3/2006. PMID: 16242257.
173. Liao Z, Liu H, Swisher SG, Wang L, Wu TT, Correa AM, Roth JA, Cox JD, Komaki R, Ajani JA, Wei Q. Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 64(3):700-8, 3/2006. PMID: 16242255.
174. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 106(5):1017-25, 3/2006. PMID: 16456809.
175. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, Ajani JA. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24(5):748-54, 2/2006. PMID: 16401681.
176. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Bresalier RS, Roth JA, Ajani JA. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 106(3):552-8, 2/2006. PMID: 16353210.
177. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB, 3rd, Yanagihara R, Phan AT, Yao JC, Strumberg D. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24(4):663-7, 2/2006. PMID: 16446338.
178. Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 24(2):259-67, 1/2006. PMID: 16344314.
179. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Lahoti S, Lee JH, Bresalier R, Roth JA, Swisher SG. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg 131(1):65-72, 2006. PMID: 16399296.
180. Rohatgi PR, Correa AM, Swisher SG, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Lee JH, Rice DC, Roth JA, Ajani JA. Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. Dis Esophagus 19(3):152-7, 2006. PMID: 16722991.
181. Tetzlaff ED, Faust J, Ajani JA. Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. Gastric Cancer 9(2):140-3, 2006. PMID: 16767371.
182. Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 104(11):2365-72, 12/2005. PMID: 16245310.
183. Das P, Ajani JA. Gastric and gastro-oesophageal cancer therapy. Expert Opin Pharmacother 6(16):2805-12, 12/2005. PMID: 16318431.
184. Izzo JG, Malhotra U, Wu TT, Ensor J, Babenko IM, Swisher SG, Correa A, Bresalier RS, Hittelman WN, Ajani JA. Impact of cyclin D1 A870G polymorphism in esophageal adenocarcinoma tumorigenesis. Semin Oncol 32(6 Suppl 9):S11-5, 12/2005. PMID: 16399423.
185. Song S, Lippman SM, Zou Y, Ye X, Ajani JA, Xu XC. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene 24(56):8268-76, 12/2005. PMID: 16170369.
186. Wu X, Lu C, Chiang SS, Ajani JA. Pharmacogenetics in esophageal cancer. Semin Oncol 32(6 Suppl 9):S87-9, 12/2005. PMID: 16399440.
187. Shao L, Lin J, Huang M, Ajani JA, Wu X. Predictors of esophageal cancer risk: assessment of susceptibility to DNA damage using comet assay. Genes Chromosomes Cancer 44(4):415-22, 12/2005. PMID: 16114035.
188. Ajani JA, Takimoto C, Becerra CR, Silva A, Baez L, Cohn A, Major P, Kamida M, Feit K, De Jager R. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs 23(5):479-84, 10/2005. PMID: 16133799.
189. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, Ajani JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 104(7):1349-55, 10/2005. PMID: 16130133.
190. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8):1590-602, 10/2005. PMID: 16134179.
191. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23(28):6957-65, 10/2005. PMID: 16145066.
192. Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104(8):1620-6, 10/2005. PMID: 16118804.
193. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23(24):5660-7, 8/2005. PMID: 16110025.
194. Varadhachary G, Ajani JA. Preoperative and adjuvant therapies for upper gastrointestinal cancers. Expert Rev Anticancer Ther 5(4):719-25, 8/2005. PMID: 16111471.
195. Liu L, Hofstetter WL, Rashid A, Swisher SG, Correa AM, Ajani JA, Hamilton SR, Wu TT. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol 29(8):1079-85, 8/2005. PMID: 16006804.
196. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer,, II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol 23(13):3094-103, 5/2005. PMID: 15860869.
197. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 241(5):810-7; discussion 817-20, 5/2005. PMID: 15849517.
198. Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA, Xu XC. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 26(4):785-91, 4/2005. PMID: 15661803.
199. Xu XC, Lee JJ, Wu TT, Hoque A, Ajani JA, Lippman SM. Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 14(4):826-9, 4/2005. PMID: 15824151.
200. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103(7):1347-55, 4/2005. PMID: 15719440.
201. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 61(3):656-64, 3/2005. PMID: 15708243.
202. Chirieac LR, Swisher SG, Correa AM, Ajani JA, Komaki RR, Rashid A, Hamilton SR, Wu TT. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res 11(6):2229-36, 3/2005. PMID: 15788671.
203. Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11(4):1386-93, 2/2005. PMID: 15746037.
204. Varadhachary G, Ajani JA. Gastric cancer. Clin Adv Hematol Oncol 3(2):118-24, 2/2005. PMID: 16166979.
205. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23(6):1237-44, 2/2005. PMID: 15718321.
206. Rice DC, Correa AM, Vaporciyan AA, Sodhi N, Smythe WR, Swisher SG, Walsh GL, Putnam JB, Jr, Komaki R, Ajani JA, Roth JA. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg 79(2):391-7; discussionn 391-7, 2/2005. PMID: 15680801.
207. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 11(2 Pt 1):656-63, 1/2005. PMID: 15701853.
208. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Walsh GL, Vaporciyan AA, Rice DC, Fukami N, Roth JA, Ajani JA. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer 36(2):69-76, 2005. PMID: 16648656.
209. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 10 Suppl 3:49-58, 2005. PMID: 16368871.
210. Wang L, Shi GG, Yao JC, Gong W, Wei D, Wu TT, Ajani JA, Huang S, Xie K. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer 8(1):18-28, 2005. PMID: 15747170.
211. Tetzlaff ED, Ajani JA. Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. Int J Gastrointest Cancer 36(1):55-8, 2005. PMID: 16227636.
212. Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys 60(5):1484-93, 12/2004. PMID: 15590179.
213. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22(23):4762-71, 12/2004. PMID: 15570077.
214. Ajani JA. Irinotecan and other agents in the management of multiple tumor types: highlights from the 6th University of Texas M. D. Anderson Cancer Center Investigators' Workshop. Oncology (Huntingt). 18(14 Suppl 14):7-9, 12/2004.
215. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101(8):1776-85, 10/2004. PMID: 15386332.
216. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78(4):1152-60; discussion 1152-60, 10/2004. PMID: 15464463.
217. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 101(3):518-26, 8/2004. PMID: 15274064.
218. Whiting J, Sano T, Sasako M, Ajani JA. Report of the Seventeenth International Symposium of the Foundation for Promotion of Cancer Research: Recent Advances in Gastric Cancer. Jpn J Clin Oncol 34(8):481-8, 8/2004. PMID: 15371468.
219. Harting MT, Blakely ML, Herzog CE, Lally KP, Ajani JA, Andrassy RJ. Treatment issues in pediatric gastric adenocarcinoma. J Pediatr Surg 39(8):e8-10, 8/2004. PMID: 15300556.
220. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22(14):2774-80, 7/2004. PMID: 15254045.
221. Benson AB, 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, Jr, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918-26, 7/2004. PMID: 15254061.
222. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB, Jr, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100(11):2347-54, 6/2004. PMID: 15160337.
223. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 22(10):1785-96, 5/2004. PMID: 15067027.
224. Higuchi K, Koizumi W, Tanabe S, Saigenji K, Ajani JA. Chemotherapy is more active against proximal than distal gastric carcinoma. Oncology 66(4):269-74, 2004. PMID: 15218293.
225. Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus 17(1):38-43, 2004. PMID: 15209739.
226. Lee HK, Vaporciyan AA, Cox JD, Tucker SL, Putnam JB, Jr, Ajani JA, Liao Z, Swisher SG, Roth JA, Smythe WR, Walsh GL, Mohan R, Liu HH, Mooring D, Komaki R. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys 57(5):1317-22, 12/2003. PMID: 14630268.
227. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, Xie K. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9(17):6371-80, 12/2003. PMID: 14695137.
228. Higuchi K, Phan A, Ajani JA. Gastric cancer: advances in adjuvant and adjunct therapy. Curr Treat Options Oncol 4(5):413-9, 10/2003. PMID: 12941201.
229. Swisher SG, Ajani JA, Komaki R, Nesbitt JC, Correa AM, Cox JD, Lahoti S, Martin F, Putnam JB, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 57(1):120-7, 9/2003. PMID: 12909224.
230. Xiong HQ, Gunderson LL, Yao J, Ajani JA. Chemoradiation for resectable gastric cancer. Lancet Oncol 4(8):498-505, 8/2003. PMID: 12901965.
231. Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 9(4):261-7, 7/2003. PMID: 12967136.
232. Lisenko Y, Kumar AJ, Yao J, Ajani J, Ho L. Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol 26(2):165-70, 4/2003. PMID: 12714889.
233. Hung A, Crane C, Delclos M, Ballo M, Ajani J, Lin E, Feig B, Skibber J, Janjan N. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer 97(5):1195-202, 3/2003. PMID: 12599225.
234. Schnirer,, II, Yao JC, Ajani JA. Carcinoid--a comprehensive review. Acta Oncol 42(7):672-92, 2003. PMID: 14690153.
235. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 14 Suppl 2:ii41-4, 2003. PMID: 12810457.
236. Wang L, Gong W, Wei D, Peng Z, Wu T-T, Ajani JA, Xie K. Expression of Transcription Factor Sp1 Predicts the Microvessel Density of Human Gastric Cancer: Contribution of Increased VEGF Expression. Clinical Cancer Res, 2003.
237. Zheng L, Wang L, Ajani JA, K Xie. Molecular Basis of Gastric Cancer Development and progression. Gastric Cancer, 2003.
238. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 9(1):134-42, 2003. PMID: 12538461.
239. Windham TC, Termuhlen PM, Ajani JA, Mansfield PF. Adenocarcinoma of the stomach in patients age 35 years and younger: no impact of early diagnosis on survival outcome. J Surg Oncol 81(3):118-24; discussion 124-5, 11/2002. PMID: 12407722.
240. Gunderson LL, Sargent DJ, Tepper JE, O'Connell MJ, Allmer C, Smalley SR, Martenson JA, Haller DG, Mayer RJ, Rich TA, Ajani JA, Macdonald JS, Goldberg RM. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys 54(2):386-96, 10/2002. PMID: 12243812.
241. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Jr, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Treatment outcomes of resected esophageal cancer. Ann Surg 236(3):376-84; discussion 384-5, 9/2002. PMID: 12192324.
242. Hasham-Jiwa N, Kasakura Y, Ajani JA. Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995-2001. Int J Clin Oncol 7(4):219-24, 8/2002. PMID: 12202975.
243. Kasakura Y, Ajani JA, Mochizuki F, Morishita Y, Fujii M, Takayama T. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol 80(4):181-5, 8/2002. PMID: 12210031.
244. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park) 16(5 Suppl 5):16-8, 5/2002. PMID: 12109800.
245. Kasakura Y, Ajani JA, Fujii M, Mochizuki F, Takayama T. Management of perforated gastric carcinoma: a report of 16 cases and review of world literature. Am Surg 68(5):434-40, 5/2002. PMID: 12013286.
246. Ajani JA. [Is neoadjuvant therapy for locally advanced stomach carcinoma standard?]. Chirurg 73(4):312-5, 4/2002. PMID: 12063914.
247. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 94(3):641-6, 2/2002. PMID: 11857295.
248. Yao JC, Schnirer,, II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, Ajani JA. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer 5(4):208-12, 2002. PMID: 12491078.
249. Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, Ajani JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 123(1):175-83, 2002. PMID: 11782772.
250. Yao JC Ajani JA. Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol 13 Suppl 4:7-12, 2002. PMID: 12401660.
251. Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, Gagel RF, Ajani JA, Wolff RA, Evans DB. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130(6):1078-85, 12/2001. PMID: 11742342.
252. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725-30, 9/2001. PMID: 11547741.
253. Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, Ajani JA, Mansfield PF. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 8(6):519-24, 7/2001. PMID: 11456051.
254. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92(2):279-86, 7/2001. PMID: 11466680.
255. Schnirer,, II, Komaki R, Yao JC, Swisher S, Putnam J, Pisters PW, Roth JA, Ajani JA. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol 24(1):91-5, 2/2001. PMID: 11232959.
256. Willett C, Ajani J, Kelsen D, Sigurdson E, Abrams R, Berkey B, Benetz M, Crane C, Gaspar L, Goodyear MD, Gunderson L, Haddock M, Hoffmann J, Janjan N, John M, Kachnic L, Krieg R, Landry J, Meropol N, Minsky B, Mitchell E, Mohiuddin M, Moulder J, Myerson R, Noyes D, Pajak TF, Raben D, Regine W, Rich T, Robertson JM, Russell A, Skibber J, Kim P. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys 51(3 Suppl 2):19-27, 2001. PMID: 11641011.
257. Pro B, Lozano R, Ajani JA. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs 19(4):341-3, 2001. PMID: 11561696.
258. Ajani JA. [Strategies for preoperative therapy of locoregional cancers: an opportunity for expanding current concepts]. Chirurg 71(12):1431-2, 12/2000. PMID: 11195060.
259. Komaki R, Janjan NA, Ajani JA, Lynch PM, Fairweather JS, Raijman I, Blumenshein GR, Ho L, Pisters PW, Feig BW, Walsh GL, Pazdur R. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology (Williston Park) 14(12 Suppl 14):34-7, 12/2000. PMID: 11200147.
260. Ajani JA. The evolving role of irinotecan: a broad-spectrum chemotherapeutic agent. Introduction. Oncology (Williston Park) 14(12 Suppl 14):17-8, 12/2000. PMID: 11200142.
261. Swisher SG, Deford L, Merriman KW, Walsh GL, Smythe R, Vaporicyan A, Ajani JA, Brown T, Komaki R, Roth JA, Putnam JB. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 119(6):1126-32, 6/2000. PMID: 10838528.
262. Ajani JA, Yao JC. Preoperative therapy for local-regional gastric cancer: rationale and review of trials. Gan To Kagaku Ryoho 27 Suppl 2:392-4, 5/2000. PMID: 10895184.
263. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J 6(2):78-81, 3/2000. PMID: 11069223.
264. Medgyesy CD, Wolff RA, Putnam JB, Jr, Ajani JA. Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. Cancer 88(2):262-7, 1/2000. PMID: 10640955.
265. York JE, Stringer J, Ajani JA, Wildrick DM, Gokaslan ZL. Gastric cancer and metastasis to the brain. Ann Surg Oncol 6(8):771-6, 12/1999. PMID: 10622506.
266. Yao JC, Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma: closing out the century. Oncology (Williston Park) 13(11):1485-94; discussion 1497-502 passim, 11/1999. PMID: 10581599.
267. Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer 86(9):1657-68, 11/1999. PMID: 10547537.
268. Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 17(8):2403-11, 8/1999. PMID: 10561303.
269. Partyka S, Dumas P, Ajani J. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma. Cancer 85(11):2336-9, 6/1999. PMID: 10357402.
270. Bold RJ, Ota DM, Ajani JA, Mansfield PF. Peritoneal and serum tumor markers predict recurrence and survival of patients with resectable gastric cancer. Gastric Cancer 2(1):1-7, 5/1999. PMID: 11957063.
271. Janjan NA, Abbruzzese J, Pazdur R, Khoo VS, Cleary K, Dubrow R, Ajani J, Rich TA, Goswitz MS, Evetts PA, Allen PK, Lynch PM, Skibber JM. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol 51(2):153-60, 5/1999. PMID: 10435807.
272. Ajani JA, Mansfield PF, Dumas P. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am 5(2):112-4, 3/1999. PMID: 10198733.
273. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229(3):303-8, 3/1999. PMID: 10077040.
274. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17(2):600-6, 2/1999. PMID: 10080605.
275. Thomas E, Dumas P, Ajani JA. Oral etoposide for patients with advanced adenocarcinoma of the pancreas. Invet New Drugs 16:333-335, 1999.
276. Kim YH, Ajani JA, Carrasco CH, Dumas P, Richli W, Lawrence D, Chuang V, Wallace S. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 17(7):474-8, 1999. PMID: 10518191.
277. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339(27):1979-84, 12/1998. PMID: 9869669.
278. Raijman I, Siddique I, Ajani J, Lynch P. Palliation of malignant dysphagia and fistulae with coated expandable metal stents: experience with 101 patients. Gastrointest Endosc 48(2):172-9, 8/1998. PMID: 9717783.
279. Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol 16(8):2877-85, 8/1998. PMID: 9704742.
280. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4(4):269-74, 7/1998. PMID: 9689986.
281. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16(5):1826-34, 5/1998. PMID: 9586897.
282. Rivera E Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21(1):36-8, 2/1998. PMID: 9499254.
283. Diamandidou E, Ajani JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, Lawrence DD, Wallace S. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol 170(2):339-44, 2/1998. PMID: 9456942.
284. Ajani JA et al. NCCN Practice guidelines for upper gastrointestinal carcinomas. Oncology (USA) 12(11A):179-213, 1998.
285. Thomas E, Dumas P, Ajani JA. Oral etoposide for patients with advanced adenocarcinoma of the pancreas. Invest New Drugs 16(4):333-5, 1998. PMID: 10426667.
286. Ajani JA, Pazdur R, Dumas P, Fairweather J. Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma. Invest New Drugs 16(2):175-7, 1998. PMID: 9848582.
287. Pazdur R, Meyers C, Diaz-Canton E, Abbruzzese JL, Patt Y, Grove W, Ajani J. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol 20(6):573-6, 12/1997. PMID: 9391543.
288. Lowy AM, Mansfield PF, Leach SD, Ajani J. Laparoscopic staging for gastric cancer. Surgery 119(6):611-4, 6/1996. PMID: 8650600.
289. Wallace S, Ajani JA, Charnsangavej C, DuBrow R, Yang DJ, Chuang VP, Carrasco CH, Dodd GD, Jr. Carcinoid tumors: imaging procedures and interventional radiology. World J Surg 20(2):147-56, 2/1996. PMID: 8661810.
290. Jeon HM, Lynch PM, Howard L, Ajani J, Levin B, Frazier ML. Mutation of the hMSH2 gene in two families with hereditary nonpolyposis colorectal cancer. Hum Mutat 7(4):327-33, 1996. PMID: 8723682.
291. Pazdur R, Bready B, Ajani JA, Abbruzzese JL, Markowitz A, Sugarman S, Jones D, Levin B. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Am J Clin Oncol 18(5):436-8, 10/1995. PMID: 7572763.
292. Rich TA, Skibber JM, Ajani JA, Buchholz DJ, Cleary KR, Dubrow RA, Levin B, Lynch PM, Meterissian SH, Roubein LD, et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 32(4):1025-9, 7/1995. PMID: 7607922.
293. Weinstein GD, Rich TA, Shumate CR, Skibber JM, Cleary KR, Ajani JA, Ota DM. Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. Int J Radiat Oncol Biol Phys 32(1):197-204, 4/1995. PMID: 7721616.
294. Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg 19(2):216-20, 3/1995. PMID: 7754626.
295. Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer 75(2):451-6, 1/1995. PMID: 7812915.
296. Ajani JA, Roth JA, Putnam JB, Walsh G, Lynch PM, Roubein LD, Ryan MB, Natrajan G, Gould P. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Eur J Cancer 31A(5):665-70, 1995. PMID: 7640036.
297. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV, Jr, Markowitz AB, Abbruzzese JL, Bready B, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12(11):2296-300, 11/1994. PMID: 7964943.
298. Philip PA, Ajani JA. Has combined modality therapy improved the outlook in carcinoma of the esophagus? Oncology (Williston Park) 8(9):37-42; discussion 44-5, 50-2, 61, 9/1994. PMID: 7527642.
299. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86(14):1086-91, 7/1994. PMID: 7912736.
300. Pazdur R, Lassere Y, Soh LT, Ajani JA, Bready B, Soo E, Sugarman S, Patt Y, Abbruzzese JL, Levin B. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol 5(5):468-70, 5/1994. PMID: 7915537.
301. Meterissian S, Skibber J, Rich T, Roubein L, Ajani J, Cleary K, Ota DM. Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. Ann Surg Oncol 1(2):111-6, 3/1994. PMID: 7834435.
302. Moore DF, Jr, Pazdur R, Abbruzzese JL, Ajani JA, Dubovsky DW, Wade JL, 3rd, Belt RJ, Mangold C, Bready B, Winn RJ. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol 5(3):286-7, 3/1994. PMID: 8186177.
303. Ajani JA, Dodd LG, Daugherty K, Warkentin D, Ilson DH. Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst 86(1):51-3, 1/1994. PMID: 7903699.
304. Rich TA, Evans DB, Curley SA, Ajani JA. Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. Ann Oncol 5 Suppl 3:75-80, 1994. PMID: 8204533.
305. Rich TA, Ajani JA. High dose external beam radiation therapy with or without concomitant chemotherapy for esophageal carcinoma. Ann Oncol 5 Suppl 3:9-15, 1994. PMID: 8204536.
306. Ajani JA, Winn R, Baez L, Pollock T, Maher T, Hallinan-Fueger B, Newman J. Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma. Cancer Invest 12(5):488-90, 1994. PMID: 7922705.
307. Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, Sellin RV, Fenoglio CJ, Merrell RC, Hickey RC. Nonfunctioning islet cell carcinoma of the pancreas. Surgery 114(6):1175-81; discussion 1181-2, 12/1993. PMID: 7903005.
308. Jones DV, Jr, Patt YZ, Ajani JA, Abbruzzese J, Carrasco CH, Charnsangavej C, Levin B, Wallace S. A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Cancer 72(9):2560-3, 11/1993. PMID: 8402476.
309. Roubein LD, DuBrow R, David C, Lynch P, Fornage B, Ajani J, Roth J, Levin B. Endoscopic ultrasonography in the quantitative assessment of response to chemotherapy in patients with adenocarcinoma of the esophagus and esophagogastric junction. Endoscopy 25(9):587-91, 11/1993. PMID: 8119209.
310. Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, Sugarbaker DJ, Dumas P, Gray C, Vena DA, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 85(22):1839-44, 11/1993. PMID: 8230264.
311. Rich TA, Ajani JA, Morrison WH, Ota D, Levin B. Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol 27(3):209-15, 6/1993. PMID: 8210457.
312. Shumate CR, Rich TA, Skibber JM, Ajani JA, Ota DM. Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. Cancer 71(11):3690-6, 6/1993. PMID: 8490919.
313. Pazdur R, Ajani JA, Patt YZ, Gomez J, Bready B, Levin B. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer 71(4):1214-8, 2/1993. PMID: 8435795.
314. Ajani JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs 11(1):67-9, 2/1993. PMID: 8349439.
315. Jones DV, Jr, Ajani JA, Winn RJ, Daugherty KR, Levin B, Krakoff IH. A phase II study of merbarone in patients with adenocarcinoma of the pancreas. Cancer Invest 11(6):667-9, 1993. PMID: 8221199.
316. Ajani JA, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, Gutterman JU, McMurtrey M. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 11(1):22-8, 1993. PMID: 8418237.
317. Ajani JA, Chesnut JR. Response to increasing doses of octreotide in a patient with carcinoid syndrome. Eur J Cancer 29A(16):2332-3, 1993. PMID: 7509166.
318. Ajani JA, Dumas P. Evaluation of oral etoposide in patients with metastatic gastric carcinoma: a preliminary report. Semin Oncol 19(6 Suppl 14):45-7, 12/1992. PMID: 1488653.
319. Hubbard KP, Pazdur R, Ajani JA, Braud E, Blaustein A, King M, Llenado-Lee M, Winn R, Levin B, Abbruzzese JL. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol 15(6):524-7, 12/1992. PMID: 1449117.
320. Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, Graham S, Pilat S, Winn R, Levin B. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 70(8):2073-6, 10/1992. PMID: 1394037.
321. Jones DV, Jr, Samaan NA, Sellin RV, Ajani JA. Metastatic glucagonoma: clinical response to a combination of 5-fluorouracil and alpha-interferon. Am J Med 93(3):348-9, 9/1992. PMID: 1524091.
322. Jones DV, Jr, Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ, Abbruzzese JL. Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs 10(3):211-3, 8/1992. PMID: 1428730.
323. Grossie VB, Jr, Nishioka K, Ajani JA, Ota DM. Substituting ornithine for arginine in total parenteral nutrition eliminates enhanced tumor growth. J Surg Oncol 50(3):161-7, 7/1992. PMID: 1619938.
324. Hubbard KP, Daugherty K, Ajani JA, Pazdur R, Levin B, Abbruzzese JL. Phase II trial of fazarabine in advanced colorectal carcinoma. Invest New Drugs 10(1):39-42, 4/1992. PMID: 1376722.
325. Pazdur R, Ajani JA, Winn R, Bearden J, Belt RJ, Pilat S, Hallinan R, Levin B. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma. Cancer 69(4):878-82, 2/1992. PMID: 1735078.
326. Kim EE, Chung SK, Haynie TP, Kim CG, Cho BJ, Podoloff DA, Tilbury RS, Yang DJ, Yung WKA, Moser RP, Ajani JA. Differentiation of residual or recurrent tumors from post-treatment changes with PET using 18F-FDG. Radiographics 12:269-275, 1992.
327. Ajani JA, Ryan B, Rich TA, McMurtrey M, Roth JA, DeCaro L, Levin B, Mountain C. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer 28A(4-5):880-4, 1992. PMID: 1524915.
328. Grossie VB, Jr, Ota DM, Ajani JA, Nishioka K. Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine. Invest New Drugs 9(4):321-6, 11/1991. PMID: 1804805.
329. Linke K, Pazdur R, Abbruzzese JL, Ajani JA, Winn R, Bradof JE, Daugherty K, Levin B. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs 9(4):353-6, 11/1991. PMID: 1804812.
330. Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Belt R, Young J, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. Invest New Drugs 9(4):369-71, 11/1991. PMID: 1804816.
331. Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 68(7):1501-6, 10/1991. PMID: 1893349.
332. Robey-Cafferty SS, Ajani JA, Ota DM, Roth JA, Bruner JM. Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. Arch Pathol Lab Med 115(8):807-12, 8/1991. PMID: 1713759.
333. Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Wiseman C, Lenado-Lee MA, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. Invest New Drugs 9(3):257-9, 8/1991. PMID: 1783525.
334. Nishioka K, Grossie VB, Chang TH, Ajani JA, Ota DM. Colorectal ornithine decarboxylase activity in human mucosa and tumors: elevation of enzymatic activity in distal mucosa. J Surg Oncol 47(2):117-20, 6/1991. PMID: 2062082.
335. Dhingra K, Talpaz M, Dhingra HM, Ajani JA, Rothberg JM, Gutterman JU. A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum. Invest New Drugs 9(1):37-9, 2/1991. PMID: 1851142.
336. Ellerbroek NA, Fossella FV, Rich TA, Ajani JA, Komaki R, Roth JA, Holoye PY. Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 20(2):351-5, 2/1991. PMID: 1846848.
337. Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintuch J, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8(12):2027-31, 12/1990. PMID: 2230894.
338. Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Pazdur R, Saks S, Edwards C, Gutterman JU. A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Mod 9(5):522-7, 10/1990. PMID: 2123922.
339. Ajani JA, Roth JA, Ryan B, McMurtrey M, Rich TA, Jackson DE, Abbruzzese JL, Levin B, DeCaro L, Mountain C. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 8(7):1231-8, 7/1990. PMID: 2358838.
340. Patt YZ, Lamki LM, Shanken J, Jessup JM, Charnsangavej C, Ajani JA, Levin B, Merchant B, Halverson C, Murray JL. Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol 8(7):1246-54, 7/1990. PMID: 2193120.
341. Venkatesh S, Ordonez NG, Ajani J, Schultz PN, Hickey RC, Johnston DA, Samaan NA. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer 65(2):354-7, 1/1990. PMID: 2153046.
342. Ajani JA, Abbruzzese JL, Faintuch JS, Patt YZ, Boman BM, Jackson DE, Levin B, Krakoff IH. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. Cancer Invest 8(6):619-21, 1990. PMID: 2149834.
343. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8(2):147-59, 1990. PMID: 2400936.
344. Ajani JA, Ota DM, Grossie VB, Jr, Abbruzzese JL, Faintuch JS, Patt YZ, Jackson DE, Levin B, Nishioka K. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. Cancer Chemother Pharmacol 26(3):223-6, 1990. PMID: 2113439.
345. Roth JA, Ajani JA, Rich TA. Multidisciplinary therapy for esophageal cancer. Adv Surg 23:239-60, 1990. PMID: 2403459.
346. Nicaise C, Ajani J, Goudeau P, Rozencweig M, Levin B, Krakoff I. Phase II study of tallysomycin S10b in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 26(3):221-2, 1990. PMID: 1694112.
347. Ajani JA, Carrasco CH, Samaan NA, Wallace S. Therapeutic options for patients with advanced islet cell and carcinoid tumors. Regional Cancer Treatment 3:235-242, 1990.
348. Hughes LL, Rich TA, Delclos L, Ajani JA, Martin RG. Radiotherapy for anal cancer: experience from 1979-1987. Int J Radiat Oncol Biol Phys 17(6):1153-60, 12/1989. PMID: 2599903.
349. Ajani JA, Levin B, Wallace S. Systemic and regional therapy of advanced islet cell tumors. Gastroenterol Clin North Am 18(4):923-30, 12/1989. PMID: 2559037.
350. Grossie VB, Jr, Nishioka K, Chang TH, Patenia D, Benitez MM, Ajani JA, Ota DM. Differential effects of parenteral nutrition on tumor growth and erythrocyte polyamine levels in the rat. JPEN J Parenter Enteral Nutr 13(6):590-5, 11/1989. PMID: 2515305.
351. Ajani JA, Ota DM, Grossie VB, Jr, Levin B, Nishioka K. Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels. Cancer Res 49(20):5761-5, 10/1989. PMID: 2507135.
352. Ajani JA, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med 87(2):221-4, 8/1989. PMID: 2527006.
353. Ajani JA, Kanojia MD, Bedikian AY. High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals. Am J Clin Oncol 12(4):335-8, 8/1989. PMID: 2667325.
354. Grossie VB, Jr, Ota DM, Ajani JA, Chang TH, Patenia D, Nishioka K. Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity. Cancer Res 49(15):4159-62, 8/1989. PMID: 2501023.
355. Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Saks S, Patt YZ, Edwards C, Ende K, Gutterman JU. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res 49(14):4057-61, 7/1989. PMID: 2500234.
356. Ajani JA, Rios AA, Ende K, Abbruzzese JL, Edwards C, Faintuch JS, Saks S, Gutterman JU, Levin B. Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Mod 8(2):140-6, 4/1989. PMID: 2499663.
357. Tueni EA, Newman RA, Baker FL, Ajani JA, Fan D, Spitzer G. In vitro activity of bleomycin, tallysomycin S10b, and liblomycin against fresh human tumor cells. Cancer Res 49(5):1099-102, 3/1989. PMID: 2465080.
358. Ajani JA, Goudeau P, Levin B, Faintuch JS, Abbruzzese JL, Boman BM, Kanojia MD. Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. Cancer Chemother Pharmacol 24(1):41-4, 1989. PMID: 2720890.
359. Ajani JA, Abbruzzese JL, Goudeau P, Faintuch JS, Yeomans AC, Boman BM, Nicaise C, Levin B. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 6(11):1703-7, 11/1988. PMID: 3141592.
360. Nishioka K, Grossie VB, Jr, Ajani JA, Patenia D, Chang TH, Ota DM. Polyamine-directed preferential nutritional repletion of normal tissues in tumor-bearing hosts. Int J Cancer 42(5):744-7, 11/1988. PMID: 3141298.
361. Boman BM, Gagen MM, Bonnem E, Ajani JA, Schmidt S, Dimery IW, Golando J, Neidhart J. Phase I study of recombinant gamma-interferon (rIFN-gamma). J Biol Response Mod 7(5):438-46, 10/1988. PMID: 3141591.
362. Grossie VB, Jr, Ota DM, Ajani JA, Chang TH, Patenia D, Nishioka K. Influence of total parenteral nutrition on tumor growth and polyamine biosynthesis of fibrosarcoma-bearing rats after induced cachexia. JPEN J Parenter Enteral Nutr 12(5):441-4, 9/1988. PMID: 3141639.
363. Fan D, Baker FL, Khokhar AR, Ajani JA, Tomasovic B, Newman RA, Brock WA, Tueni E, Spitzer G. Antitumor activity against human tumor samples of cis-diamminedichloroplatinum(II) and analogues at equivalent in vitro myelotoxic concentrations. Cancer Res 48(11):3135-9, 6/1988. PMID: 3365698.
364. Ajani JA, Baker FL, Spitzer G. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs 6(2):79-85, 6/1988. PMID: 3170133.
365. Ajani JA, Abbruzzese JL, Faintuch JS, Blackburn R, Levin B, Boman BM. Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. Invest New Drugs 6(1):47-50, 4/1988. PMID: 2457566.
366. Baker FL, Ajani J, Spitzer G, Tomasovic BJ, Williams M, Finders M, Brock WA. High colony-forming efficiency of primary human tumor cells cultured in the adhesive-tumor-cell culture system: improvements with medium and serum alterations. Int J Cell Cloning 6(2):95-105, 3/1988. PMID: 3373036.
367. Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med 108(3):340-4, 3/1988. PMID: 2449109.
368. Baker FL, Spitzer G, Ajani JA, Brock WA. Drug and radiation sensitivity testing of primary human tumor cells using the adhesive-tumor-cell culture system (ATCCS). Prog Clin Biol Res 276:105-17, 1988. PMID: 3174675.
369. Ajani JA, Baker FL, Spitzer G, Kelly A, Brock W, Tomasovic B, Singletary SE, McMurtrey M, Plager C. Comparison between clinical response and in vitro drug sensitivity of primary human tumors in the adhesive tumor cell culture system. J Clin Oncol 5(12):1912-21, 12/1987. PMID: 3681375.
370. Fan D, Ajani JA, Baker FL, Tomasovic B, Brock WA, Spitzer G. Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an in vitro method of screening new drugs. Eur J Cancer Clin Oncol 23(10):1469-76, 10/1987. PMID: 2890527.
371. Ajani JA, Hortobagyi GN, Frye D, Levin B, Boman BM, Faintuch JS. A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma. Am J Clin Oncol 10(2):139-40, 4/1987. PMID: 3551577.
372. Grossie VB, Jr, Ota DM, Ajani JA, Nishioka K. Effect of intravenous alpha-difluoromethylornithine on the polyamine levels of normal tissue and a transplantable fibrosarcoma. Cancer Res 47(7):1836-40, 4/1987. PMID: 3102050.
373. Odaimi M, Ajani J. High-dose chemotherapy. Concepts and strategies. Am J Clin Oncol 10(2):123-32, 4/1987. PMID: 3551575.
374. Singletary SE, Baker FL, Spitzer G, Tucker SL, Tomasovic B, Brock WA, Ajani JA, Kelly AM. Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res 47(2):403-6, 1/1987. PMID: 3491676.
375. Odaimi M, Ajani JA. Brain metastases and elevated alpha-fetoprotein level in a patient with esophageal carcinoma. South Med J 79(10):1304-6, 10/1986. PMID: 2429372.
376. Ajani JA, Spitzer G, Tomasovic B, Drewinko B, Hug VM, Dicke K. In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells. Br J Cancer 54(4):607-13, 10/1986. PMID: 3778805.
377. Patt YZ, Boddie AW, Jr, Charnsangavej C, Ajani JA, Wallace S, Soski M, Claghorn L, Mavligit GM. Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. J Clin Oncol 4(9):1356-64, 9/1986. PMID: 2943876.
378. Ota DM, Grossie VB, Jr, Ajani JA, Stephens LC, Nishioka K. Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion. Int J Cancer 38(2):245-9, 8/1986. PMID: 3089944.
379. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 147(1):149-54, 7/1986. PMID: 2424291.
380. Adolphson CC, Ajani JA, Stroehlein JR, Barlogie B, Bodey GP, Korinek J, Bedikian AY. Phase II trial of acivicin in patients with advanced colorectal carcinoma. Am J Clin Oncol 9(3):189-91, 6/1986. PMID: 3728371.
381. Baker FL, Spitzer G, Ajani JA, Brock WA, Lukeman J, Pathak S, Tomasovic B, Thielvoldt D, Williams M, Vines C, et al. Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium. Cancer Res 46(3):1263-74, 3/1986. PMID: 3484678.
382. Ajani JA, Dimery I, Chawla SP, Pinnamaneni K, Benjamin RS, Legha SS, Krakoff IH. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. Cancer Treat Rep 70(3):375-9, 3/1986. PMID: 3955548.
383. Ajani JA, Tomasovic B, Spitzer G, Kavanagh JJ, Thielvoldt D, Baker FL, Gershenson D. Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay. Invest New Drugs 4(2):141-8, 1986. PMID: 2426218.
384. Grossie VB, Nishioka K, Ota DM, Ajani JA, Chang TH. Ornithine decarboxylase activity of normal tissue from tumor-bearing rats. J Nutr Growth Cancer 3:13-18, 1986.
385. Hortobagyi G, Papadoupoulos N, Frye D, Ajani J, Reuben JM. Phase I clinical studies of Nafazatrom. Invest N Drugs 4:251-255, 1986.
386. Ajani JA, Faintuch JS, McClure RK, Levin B, Boman BM, Krakoff IH. Phase II study of spirogermanium in patients with advanced colorectal carcinoma. Invest New Drugs 4(4):383-5, 1986. PMID: 3583645.
387. Umbach GE, Spitzer G, Ajani JA, Hug V, Thames H, Rudolph FB, Drewinko B. Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate. J Cancer Res Clin Oncol 111(3):273-6, 1986. PMID: 3733857.
388. Grossie VB, Nishioka K, Ajani JA, Ota DM, Chang T, Patenia, D. The effect of spontaneous and induced cachexia on hepatic and tumor polyamine metabolism. J Nutrit Growth Cancer 3:143-150, 1986.
389. Feldman LD, Ajani JA. Fluorouracil-associated dermatitis of the hands and feet. Jama 254(24):3479, 12/1985. PMID: 2933539.
390. Harris WB, Grossie VB, Ota DM, Nishioka K, Ajani JA, Chang T, Patenia D. Effect of difluoromethylornithine on host and tumor polyamine metabolism during total parenteral nutrition. J Surg Res 38(6):592-8, 6/1985. PMID: 3925242.
391. Singletary SE, Umbach GE, Spitzer G, Drewinko B, Tomasovic B, Ajani J, Hug V, Blumenschein G. The human tumor stem cell assay revisited. Int J Cell Cloning 3(2):116-28, 3/1985. PMID: 3998518.
392. Ajani JA, Kanojia MD, Bedikian AY, Korinek JK, Stein SH, Espinoza EG, Bodey GP. Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma. Am J Clin Oncol 8(1):69-71, 2/1985. PMID: 3993626.
393. Kantarjian H, Ajani JA, Karlin DA. Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology 42(2):69-71, 1985. PMID: 3921891.
394. Ajani JA, Blaauw AA, Spitzer G, Baker FL, Tomasovic B, Umbach G, Thielvoldt D, Zander AR, Dicke KA. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro. Exp Hematol 13 Suppl 16:95-100, 1985. PMID: 2580731.
395. Umbach G, Hug V, Spitzer G, Tomasovic G, Thames H, Ajani JA, Drewinko B. Responses of human bone marrow progenitor cells to fluoro-ARA-AMP, homoharringtonine, and elliptinium. Invest New Drugs 2:263-265, 1985.
396. Umbach GE, Hug V, Spitzer G, Tomasovic B, Thames H, Ajani JA, Drewinko B. Survival of human bone marrow cells after in vitro treatment with 12 anticancer drugs and implications for tumor drug sensitivity assays. J Cancer Res Clin Oncol 109(2):130-4, 1985. PMID: 3980561.
397. Ajani JA, Kanojia MD, Bodey GP. Phase II evaluation of 4'-epi-doxorubicin in patients with metastatic colorectal carcinoma. Cancer Treat Rep 68(12):1507-8, 12/1984. PMID: 6595058.
398. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 68(9):1085-91, 9/1984. PMID: 6478448.
399. Ajani JA, Kalter S, Rios A. Oncologic Emergencies: A guide for the practicing physician. Part I Drug Therapy:15-36, 8/1984.
400. Feun LG, Savaraj N, Bodey GP, Lu K, Yap BS, Ajani JA, Burgess MA, Benjamin RS, McKelvey E, Krakoff I. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res 44(8):3608-12, 8/1984. PMID: 6744283.
401. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer 53(9):1836-40, 5/1984. PMID: 6231092.
402. Ajani JA, Kalter S, Rios A. Oncologic Emergencies: A guide for the practicing physician. Part II Drug Therapy:54-63, 1984.
403. Legha SS, Ajani JA, Bodey GP. Phase I study of spirogermanium given daily. J Clin Oncol 1(5):331-6, 5/1983. PMID: 6668504.
404. Kanojia M, Kantarjian H, Ajani J, Barlogie B. High-dose cytosine arabinoside (Ara-C) in colorectal cancer. British J Cancer 48:869-871, 1983.
405. Ajani JA, Burgess MA. Multiple squamous cell carcinoma treated with intra-arterial cisplatin in a patient with rheumatoid arthritis. Cancer Treat Rep 66(11):1987-9, 11/1982. PMID: 6890408.
406. Ajani JA, Cabanillas FF, Bodey GP. Phase I trial of pentamethylmelamine. Cancer Treat Rep 66(5):1227-8, 5/1982. PMID: 6805950.

Invited Articles

1. Ajani JA. GCR Graduates From Nursery School on a Fast Track to Editorial Excellence. Gastrointest Cancer Res 4(2):39, 3/2011. PMCID: PMC3109889.
2. Cohen DJ, Ajani J. An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother 12(2):225-39, 2/2011. PMID: 21226634.
3. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G, NCCN Gastric Cancer Panel. Gastric Cancer. J Natl Compr Canc Netw 8(4):378-409, 4/2010. PMID: 20410333.
4. Ajani JA. Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! J Clin Oncol 24(34):5473-4; author reply 5474-6, 12/2006. PMID: 17135655.
5. Ajani JA. Carcinoma of the esophagus: is biology screaming in my deaf ears? J Clin Oncol 23(19):4256-8, 7/2005. PMID: 15781878.
6. Phan AT, Ajani JA. Gastric carcinoma. Curr Oncol Rep 6(3):192-8, 5/2004. PMID: 15066230.
7. Xiong HQ, Ajani JA. Treatment of colorectal cancer metastasis: the role of chemotherapy. Cancer Metastasis Rev 23(1-2):145-63, 2004. PMID: 15000155.
8. Ajani JA. Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction. Oncology (Williston Park) 17(9 Suppl 8):10-2, 9/2003. PMID: 14569840.
9. Ajani JA, Faust J, Yao J, Komaki R, Stevens C, Swisher S, Putnam JB, Vaporciyan A, Smythe R, Walsh G, Rice D, Roth J. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park) 17(9 Suppl 8):20-2, 9/2003. PMID: 14569843.
10. Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C, Ajani JA. Combined-modality therapy for gastric cancer. Semin Surg Oncol 21(4):223-7, 2003. PMID: 14648779.
11. Ajani JA. Preoperative therapy for patients with resectable squamous cell carcinoma of the esophagus: are we still confused? Ann Surg Oncol 9(7):605-6, 8/2002. PMID: 12167571.
12. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park) 16(6 Suppl 6):89-96, 6/2002. PMID: 12108902.
13. Yao JC Ajani JA. Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep 4(3):222-8, 5/2002. PMID: 11937012.
14. Ajani JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. First Line Therapy of Untreated, Advanced Gastric or Gastroesophageal Junction Carcinoma with CPT-11 Plus Cisplatin. Oncology supplement, Cancer 94(3):641-646, 2/2002.
15. Ajani JA. Docetaxel in combination for advanced gastric cancer. Gastric Cancer 5 Suppl 1:31-4, 2002. PMID: 12772885.
16. Ajani JA. Taxotere in Gastric and Esophageal Carcinomas. Semin Oncol, 2002.
17. Ajani JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park) 15(3 Suppl 5):52-4, 3/2001. PMID: 11301842.
18. Najam A Ajani JA. Anatomic consideration: Uper Gastrointestinal Tract. Atlas of Cancer, 2001.
19. Komaki R, Ajani JA et al. CPT-11 and radiotherapy. Oncology, 2001.
20. Ho L, Rashid A, Kaw M, Ajani J. Predictors of Response to Treatment of Adenocarcinoma of the Stomach. Atlas of Cancer, 2001.
21. Swisher SG, Pisters PW, Komaki R, Lahoti S, Ajani JA. Gastroesophageal junction adenocarcinoma. Curr Treat Options Oncol 1(5):387-98, 12/2000. PMID: 12057146.
22. Ajani JA, Fairweather J, Pisters PW, Charnsangavej C. Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park) 14(12 Suppl 14):19-21, 12/2000. PMID: 11200143.
23. Yao JC, Ajani JA. Gastric cancer. Curr Opin Gastroenterol 16(6):516-21, 11/2000. PMID: 17031130.
24. Ajani JA. Current Status of Treatment in the Management of Esophageal Carcinoma. Manuscript for distribution. Tampa, Florida. Conference on Esophageal carcinoma, 4/2000.
25. Ajani JA. A Review of Therapy of Colorectal Carcinoma. Ohio Conference. Canton, OH, 1/2000.
26. Ajani JA. Cisplaltin plus CPT-11 in Patients with Advanced Gastric or Gastroesophageal Junction Carcinoma. Preliminary Results of an Ongoing Phase II Study. Oncology (USA), 2000.
27. Introduction: Oncology. Sonoma meeting Oncology Thought Leader Advisory Board Meeting (Oncology supplement), 2000.
28. Introduction: Paris meeting (to be printed in Seminars in Oncology). 2000.
29. Introduction: St croix no. 1 (Oncology supplement). 2000.
30. Introduction. St croix no 2 (Oncology supplement). 2000.
31. Introduction. St. Croix no. 3 (Oncology supplement). 2000.
32. Introduction. St. Croix no. 4 (Oncology supplement). 2000.
33. Introduction. St. Croix no. 5 (Oncology supplement). 2000.
34. Ajani JA. Standard Chemotherapy for Advanced Gastric Carcinoma: Is it a myth? J Clin Oncol 18:4001-4003, 2000.
35. Ajani JA. Adjuvant Therapy of Gastric Carcinoma. Posted on WebMD.com, 12/1999.
36. Ajani JA. An Overview of the treatment of Colorectal Carcinoma. Proceeding 5th Annual Oncology Symposium. Saginaw, MI, 11/1999.
37. Ajani JA. New Developments in the Treatment of Esophageal and Gastroesophageal Junction Carcinomas. Proceeding Radiology Society of North America meeting, 11/1999.
38. Ajani JA. New Developments in the Treatment of Esophageal and Gastroesophageal Junction Carcinomas. Refresher’s Course of Radiology Society of North America, Chicago, Illinois, 11/1999.
39. Ajani JA. New Developments in the Treatment of Colorectal and Upper Gastrointestinal Carcinomas. Proceeding Russian Academy of Medical Sciences. (published in Russian in a journal book), 9/1999.
40. Ajani JA. New chemotherapy agents for gastric and esophageal carcinomas. Proceeding Japan and US Chemotherapy/Radiotherapy Symposium. Hiroshima, Japan, 4/1999.
41. Ajani JA. The value of chemoradiotherapy in the management of patients with upper gastrointestinal carcinomas. Proc 9th Anticancer Therapy Congress (SOMPS). Paris, France, 2/1999.
42. Ajani JA. Carcinoma of the esophagus. An update. Cancer Consultant, 1999.
43. Ajani JA. Chemotherapy options for patients with gastric carcinoma. Proceeding Hematology/Oncology Conference, Merida City, Mexico, 1999.
44. Ajani JA Fairweather F. Cisplaltin plus CPT-11 in Patients with Advanced Gastric or Gastroesophageal Junction Carcinoma. Preliminary Results of an Ongoing Phase II Study. Chemotherapy Conference Highlights, 1999.
45. Ajani JA. Current Therapy of Colorectal Carcinoma. Proceeding Texas Society Medical Oncology. Held in Austin:September, 1999.
46. Ajani JA. Esophageal carcinoma. An update on combined modality therapy. Proceeding Hematology/Oncology Conference, Merida City, Mexico, 1999.
47. Ajani JA, Takiuchi H. Recent developments in oral chemotherapy options for gastric carcinoma. Drugs 58 Suppl 3:85-90, 1999. PMID: 10711846.
48. Ajani JA. Carcinomas of the esophagus and stomach: An update. Medical Oncology Board Review. UT M. D. Anderson Cancer Center:23 pp., 50+ refs, 10/1998.
49. Ajani JA. Chemotherapy for gastric carcinoma: new and old options. Oncology (Williston Park) 12(10 Suppl 7):44-7, 10/1998. PMID: 9830625.
50. Ajani JA. Current status of therapy for advanced gastric carcinoma. Oncology (Williston Park) 12(8 Suppl 6):99-102, 8/1998. PMID: 9726100.
51. Ajani JA. Gastric Carcinoma Update: New drugs, new radiosensitizers, and multimodality therapy. Proceedings Eighth International Congress on Anti-Cancer Treatment. Paris, France, 2/1998.
52. Partyka S Ajani JA. Chemotherapy of colorectal cancer. Current Treat Options Gastroenterology, 1998.
53. Ajani JA. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus. Chest 113(1 Suppl):112S-119S, 1998. PMID: 9438700.
54. Ajani JA. Treatment of patients with upper gastrointestinal carcinomas. Semin Oncol 24(6 Suppl 19):S19-72-S19-76, 12/1997. PMID: 9427271.
55. Ajani JA. Current options for patients with local-regional gastric carcinoma. Proceeding Gastric Cancer Conference. Yonsai University, Seoul, Korea, 9/1997.
56. Ajani JA. Esophageal Carcinoma. Proceeding Medical Oncology Board Review. U. T. M. D. Anderson Cancer Center, Houston, TX, 9/1997.
57. Ajani JA. Gastric Carcinoma. Proceeding Medical Oncology Board Review. U. T. M. D. Anderson Cancer Center, Houston, TX, 9/1997.
58. Ajani JA. New Chemotherapy agents with properties of radiation sensitization and chemoradiotherapy in patients with gastric carcinoma. Proc Chemoradiotherapy Summit, Yosemite, CA, 4/1997.
59. Ajani JA. New and old chemotherapy agents for gastric carcinoma. International Gastric Cancer Association News, Newsletter 9, 1997.
60. Diamandidiu E Ajani JA. What treatment for this man with esophageal cancer? Primary Care and Cancer 17:2 and 6, 1997.
61. Ajani JA, Ilson DH, Kelsen DP. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Semin Oncol 23(5 Suppl 12):55-8, 10/1996. PMID: 8941411.
62. Ajani JA. Current Status of Chemotherapy of Advanced Gastric Carcinoma. Proceedings WHO Conference on Gastric Carcinoma, Seoul, Korea, 9/1996.
63. Ajani JA, Ilson D, Kelsen DP. Paclitaxel in the therapy of upper GI carcinomas. Semin Oncol 23(suppl. no. 12):55-58, 1996.
64. Ajani JA. Radiotherapy, chemotherapy, and combined modality therapy of gastric carcinoma. International Gastric Cancer Association News, April Newsletter no. 1:7, 1996.
65. Ajani JA. Too much too late. Case discussion in The Oncology Times. Patient with upper GI tumor and synchronous colon carcinoma. The Oncology Times, 1996.
66. Ajani JA, Ilson DH, Kelsen DP. The activity of paclitaxel in gastrointestinal tumors. Semin Oncol 22(5 Suppl 12):46-50; discussion 51-3, 10/1995. PMID: 7481861.
67. Ajani JA, Ilson DH, Daugherty K, Kelsen DP. Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol 22(3 Suppl 6):35-40, 6/1995. PMID: 7541155.
68. Leach SD, Lowy AM, Mansfield PF, Ajani JA. Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. J Infus Chemother 5(3):104-11, 1995. PMID: 8528966.
69. Holmes FA, Kudelka AP, Kavanagh JJ, Ajani JA, Valero V. Clinical Studies of Taxol, in, Taxane Anticancer Agents: Basic Science and Current Status. American Chemical Society Symposium, eds, G. I. Georg, T. C. Chen, I. Ojima, and D. M. Vyas:31-38, 1995.
70. Ajani JA. Current status of biology and therapy of gastric carcinoma. J Infusional Th 5:91-93, 1995.
71. Philip PA, Ajani JA. Gastrointestinal Cancer in the Elderly. Cancer Bulletin, 1995.
72. Raijman I, Wallace S, Ajani JA. Interventional Management of malignant biliary obstruction. Review of an article by MJ Shapiro to appear in Oncology, 1995.
73. Ajani JA, Mansfield P, Ota DM. Potentially resectable gastric carcinoma: Current approaches to staging and preoperative therapy. World J Surg 19:216-220, 1995.
74. Ajani JA. Therapy of carcinoma of the oesophagus: either attempt it not or succeed. Eur J Cancer 31A(5):790-3, 1995. PMID: 7640055.
75. Ajani JA. Etiology and therapy of gastric carcinoma. Proceedings 2nd Oncology Conference on Gastric Carcinoma; Athens, Greece, 9/1994.
76. Ajani JA, Carrasco CH, Wallace S. Neuroendocrine tumors metastatic to the liver. Vascular occlusion therapy. Ann N Y Acad Sci 733:479-87, 9/1994. PMID: 7978898.
77. Ajani JA. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol 21(4):474-82, 8/1994. PMID: 8042045.
78. Kelsen D, Ajani JA, Ilson D, Daugherty K, Pazdur R. A phase II trial of paclitaxel in advanced esophageal cancer. Preliminary report. Semin Oncol 21:44-48, 1994.
79. Ajani JA. Cancer of the Esophagus. Approaches to Etiology by Valda M. Craddock. Cambridge University Press. Cancer Bulletin 46:284-285, 1994.
80. Ajani JA. Carcinoma of the Esophagus. Carcinoma of the Stomach. Carcinoma of the Colon and Rectum. American College of Gastroenterology Syllabus and Q + A for the Annual Meeting in Sept. San Francisco, 1994.
81. Vassilopoulou-Sellin R, Ajani J. Islet cell tumor of the pancreas. Endocrine Clinics of North America 23:53-65, 1994.
82. Chesnut JR Ajani JA. Role of escalating dose of octreotide in the relief of carcinoid syndorme. Sandoz publication, 1994.
83. Ajani JA. Vascular Occlusion Therapy of Liver Metastases. Review: Soulen MC. Chemoembolization of hepatic malignancies. Oncology 8:90-93, 1994.
84. Ajani JA. What re the therapeutic options for a 60-year old woman with stage II well-differentiated adenocarcinoma of the proximal jejunum? The Oncology Times. Tumor Board 5:19, 1994.
85. Ajani JA. Carcinoma of the Esophagus. Staging and therapy. Proceedings ACT-AAPI-MCI Symposium. Recent Advances in Oncology. New Delhi, India:pp. 1-11. (an extended abstract), 12/1993.
86. Ajani JA. American College of Physician Medical Oncology Course. Carcinoma of the Esophagus and GE Junction. UT MDACC Course, 1993.
87. Ajani JA. American College of Physician Medical Oncology Course. Gastric Carcinoma. UT MDACC Course, 1993.
88. Ajani JA. American College of Physician Medical Oncology Course. Hepatocellular Carcinoma. UT MDACC Course, 1993.
89. Ajani JA. American College of Physician Medical Oncology Course. Pancreatic Neuroendocrine Tumors and Carcinoid Tumors. UT MDACC Course, 1993.
90. Ota DM, Ajani JA, Mansfield P. Preoperative Therapy for Gastric Carcinoma. Surgical Clinics of North America 2:493-497, 1993.
91. Ajani JA, Dumas P. Phase II study of oral etoposide in patients with gastric carcinoma: A preliminary report. Semin Oncol, 12/1992.
92. Ajani JA. Management of Gastric Cancer; edited by PH Sugarbaker, MD; Kluwer Academic Publishers; Boston/Dordrecht/London. JNCI 84:1597, 1992.
93. Ota DM, Mansfield P, Ajani JA. Operative and adjuvant treatment strategies for gastric carcinoma. Cancer Bulletin 44:286-291, 1992.
94. Ajani JA. American College of Physician Medical Oncology Course. Review of Carcinoma of the Esophagus and GE Junction, 1991.
95. Ajani JA. American College of Physician Medical Oncology Course. Review of Gastric Carcinoma, 1991.
96. Ajani JA. American College of Physician Medical Oncology Course (UT MDACC). Review of Carcinoid and Islet Cell Tumors, 1991.
97. Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer 67(1 Suppl):260-5, 1991. PMID: 1984825.
98. Rich TA, Jessup JM, Ota DM, Ames FC, Hohn DC, Martin RG, Ajani JA, Abbruzzese JL. Conservative management of anal and low rectal cancers with combined modality therapy. Cancer Bulletin, 1989.
99. Ajani JA Spitzer G. Adhesive tumor cell culture system. J Clin Oncol 6:178, 1988.
100. Ajani JA. Adjuvant chemotherapy for colorectal carcinoma. Cancer Bulletin 40:235-237, 1988.
101. Ajani JA. Book review. (Gastric Cancer. Contemporary Issues in Clinical Oncology. H. O. Douglass (ed), Churchill Livingston, New York). Cancer Bull (book review) 40:323, 1988.
102. Ajani JA Jackson DE. Carcinomas of the esophagus and stomach. Consultant 28:93-109, 1988.
103. Ajani JA. Highlights: 1988 Meeting of American Society of Clinical Oncology (ASCO 1988). New Orleans, May 23-25. J Cancer Res Clin Oncol 114:533-535, 1988.
104. Ajani JA. Value of predictive tests for clinical chemotherapy. Cancer Bull 39:263, 1987.
105. Boddie AW, Patt YZ, McBride CN, Wallace S, Ajani JA, Charnsangavej C, Soski M, Levin B. MDAH surgical experience with implantable infusaid pump and Medtronic drug administration device. International conference on Regional Therapy. Giessen, West Germany. 8/1985.
106. Feldman L Ajani J. 5-Fluorouracil induced dermatitis. JAMA, Dec, 1985.
107. Bodey GP, Yap BS, Ajani JA, Aboud AA, Yap HW, Estey EH. Clinical trials of 4'-epidoxorubicin. 13th International Congress of Chemotherapy. Vienna, Austria, SY 88, part 215, 1983.
108. Ajani JA, Sahu SK, Spitzer G, Hug V, Bodey GP. Cloning of human tumor stem cells in the soft agar - An overview. Cancer Bull 35:16-19, 1983.

Editorials

1. Ajani JA. Crescendos and decrescendos: gastric and esophageal cancers. J Natl Compr Canc Netw 9(8):811-3, 8/1/2011. PMID: 21900215.
2. Blum MA, Ajani JA. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. Onkologie 34(10):499-500, 2011. e-Pub 9/16/2011. PMID: 21985847.

Abstracts

1. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinister M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). ASCO GI Cancer Symposium (#8), 2009.
2. Ajani JA, Rodriguez W, Bodoky G, Moiseyenk V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. J Clin Oncol Suppl 27(15) (#4511), 2009.
3. Mani MA, Shroff RT, Jacobs C, Wolff RA, Ajani JA, Yao JC, Phan AT. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. J Clin Onco. ASCO Annual Mtg Proc. 26 (#15550), 5/2008.
4. Cen P, Ajani JA, Correa AM, Lee JH, Maru DM, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA. Adenocarcinoma of the lower esophagus with Barrett's or without Barrett's: differences in patients survival after preoperative chemoradiation. J Clin Oncol 26 (#4524), 5/2008.
5. Ho L, Phan AT, Jhamb J, Mani M, Tetzlaff E, Lin E, Ajani JA, Abbruzzese JL, Overman MJ. Retrospective review of docetaxel, cisplatin, and 5FU (DCF) given on a weekly basis for the treatment of advanced gastric or esophageal cancer. J Clin Onco. ASCO Annual Mtg Proc. 26 (#15525), 5/2008.
6. Overman MJ, Kopetz S, Morris J, Ajani JA, Hoff PM, Abbruzzese JL, Wolff RA. A retrospective review of platinum-based versus non-platinum based chemotherapy in the treatment of metastatic adenocarcinoma of the small bowel (SBA). GI Cancer Symposium (#172), 2007.
7. 60. Ajani JA, Phan A, Ho L, Tetzlaff ED, Baker J, Wei Q. Phase I/II trial of docetaxel plus oxaliplatin and 5-fluorouracil (D-FOX) in patients with untreated, advanced gastric or gastroesophageal cancer. J Clin Onc. ASCO Annual Mtg Proc. 25(18S) (#4612), 2007.
8. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriquez-Bigas MA, Chang GJ, Bhosale P, Krishnan S, Crane CH. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. GI Cancer Symposium (#275), 2007.
9. Zachariah B, James J, Gwede CK, Ajani JA, Chin L, Donath D, Kane BL, Rotman M, Berk L. RTOG 0315: A randomized, double-blind, placebo-controlled phase III study to determine the efficacy of octreotide acetate in preventing or reducing the severity of chemoradiation-induced diarrhea in patients with anal or rectal cancer. J Clin Onc. ASCO Annual Mtg Proc. 25(18S) (#4032), 2007.
10. Ajani JA. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho 33 Suppl 1:117-20, 6/2006. PMID: 16897985.
11. Lenz H, Lee FC, Haller DG, Singh D, Benson AB, Strumberg D, Yanagihara RH, Yao JC, Phan AT, Ajani JA. Extended saftey and efficacy data on S-1 plus cisplatin in patients with advanced gastric carcinoma in a multi-center phase II study. J Clin Onc. ASCO Annual Mtg Proc. 24(18S) (#4083), 2006.
12. Perez RP, Lewis LD, Cohen GI, Hwang J, Malik S, Marshall JL, Baker J, Phan AT, Yao JC, Ajani JA. First-in-human phase-I pharmacokinetic trial of NS-9, a liposomal poly(I);poly(C), in patients with liver metastases from various primary cancers. J Clin Onc. ASCO Annual Mtg Proc. 24(18S) (#13016), 2006.
13. Tetzlaff ED, Baker J, Ajani JA. Incidence of thrombeombolic events (TEEs) before and during chemotherapy of patients with advanced gastric and gastroesophageal junction carcinoma (AG-GEJC) on clinical trials. J Clin Onc. ASCO Annual Mtg Proc. 24(18S) (#4073), 2006.
14. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas C, Mayer RJ, Haddock MG, Willett C, Rich TA. Intergroup RTOG 98-11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. J Clin Onc. ASCO Annual Mtg Proc. 24(18S) (#4009), 2006.
15. Okawara GS, Winter K, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willet C, Ajani JA. A phase II trial of preoperative chemotherapy and chemoradiotherapy for potentially resectable adenocarcinoma of the stomach (RTOG 99-04). J Clin Onc. ASCO Annual Mtg Proc. 23(16S) (#4019), 2005.
16. Izzo JG, Wu TT, Luthra R, Luthra MG, Swisher S, Aggarwal BB, Bresalier RS, Milas L, Liao Z, Hittelman WN, Ajani JA. Association of activated transcription factor NF-kappaB with chemo-radiotherapy resistance and porr outcome in esophageal adencarcinoma. J Clin Onc. ASCO Annual Mtg Proc. 23(16S) (#4029), 2005.
17. Moiseyenko VM, Ajani JA, Tjulandin SA, Majlis A, Constenla M, Boni C, Anelli A, Yver AJ, Van Custem E. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients with metastatic gastric adenocarcinoma (MGC). J Clin Onc. ASCO Annual Mtg Proc. 23(16S) (#4002), 2005.
18. Mares JE, Worah S, Mathew SV, Charnsangavej C, Chen H, Ajani JA, Hoff PM, Phan AT, Yao JC. Increased rates hypertension (HTN) among patients with advanced carcinoid treated with bevacizumab. J Clin Onc. ASCO Annual Mtg Proc. 23(16S) (#4007), 2005.
19. Ajani JA, Phan A, Yao JC, Lee F, Singh DA, Haller D, Benson AB, Lenz H, Yanagihara RH, Strumberg D. Multi-Center Phase II Study of S-1 plus Cisplatin in patients with advanced gastric carcinoma (AGC). J Clin Onc. ASCO Annual Mtg Proc. 23(16S) (#4024), 2005.
20. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter W, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT. Number of lymph nodes with metastasis predict survival in patients with esophageal or esophagogastric junction adenocarcinoma treated with preoperative chemoradiation. J Clin Onc, ASCO Annual Mtg Proc 23(16S) (#4046), 2005.
21. Falk SJ, Anthoney A, Eatock M, van Custem E, Evans J, Valle J, Chick J, Drolet D, Ferry D, Ajani JA. Phase II pharmacokietic (PK) and pharmacodynamic (PD) study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction cancer (G/GEJC). J Clin Onc. ASCO Annual Mtg Proc. 23(16S) (#4042), 2005.
22. Izzo JG, Wu TT, Malhotra U, Ensor J, Luthra R, Chao CK, Swisher SG, Liao Z, Aggarwal BB, Hittelman WN, Ajani JA. Transcription factor NFkB a potential molecular marker predicting and improving treatment efficacy in esophageal cancer. J Clin Onc. ASCO Annual Mtg Proc. 23(16S) (#4042), 2005.
23. Becerra CR, Takimoto C, Ajani JA, Major P, Feit K, Duggal A, De Jagger R. A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previoulsy untreated metastatic gastric cancer. 2004 ASCO Annual Mtg Proc 22 (#4126), 7/2004.
24. Swisher W, Erasmus J, Maish M, Correa AM, Ajani JA, Komaki R, Cox J, Lee HK, Macaplina H, Putnam JB, Rice D, Smythe WR, Vaporciyan AV, Walsh G, Hong D, Wu TT, Roth JA. PET predicts pathologic response and long-term survival following preoperative chemoradiation in esophageal cancer. Gastrointestinal Cancer Symposium (#3), 2004.
25. Macdonald JS, Smalley S, Benedetti J, Estes N, Haller DG, Ajani JA, Gunderson LL, Jessup M, Martenson JA. Preoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: Undate of the results of Intergroup Study INT-0116 (SWOG 9008). Gastrointestinal Cancer Symposium (#6), 2004.
26. Hecht JR, Ajani JA, Michaeli D. A multicenter phase II study of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination with G17DT immunogen in patients with locally recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction previously untreated for advanced disease. Proc ASCO (#1035), 2003.
27. Hou Z, Elasmar SA, Lozano R, Hoff P, Wolff RA, Abbruzzese JL, Ajani JA, Carr K, Rashid A, Yao JC. A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma. Proc ASCO (#1508), 2003.
28. Higuchi K, Koizumi W, Tanabe S, Ajani JA. Chemotherapy is more active against proximal rather than distal gastric carcinoma. Proc ASCO (#1471), 2003.
29. Swisher S, Ajani JA, Komaki R, Putnam J, Walsh G, Liao Z, Yao J, Faust J, Wu TT, Roth J. CPT-11-taxotere-5-FU regimen for induction and concurrent chemoradiotherapy prior to surgery in patients with respectable esophageal or GEJ carcinoma. Proc ASCO (#1093), 2003.
30. Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, Boni C, Zuber E, Blattmann A. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naďve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a ranfomized phase III trial (V325). . Proc ASCO (#999), 2003.
31. Yao JC, Yeung SJ, Rashid A, Szklaruk J, Baker J, Carr K, Vauthey N, Ellis L, Curley S, Ajani JA. Early results of a phase II trial of imatinib in patients with advanced carcinioid tumor. Proc ASCO (#1491), 2003.
32. Chang BB, Bleyer AW, Faust J, Yao J, Craig C, Ajani JA. Phase II study of bryostatin-1 (NSC 339555) plus paclitaxel in patients with metastatic or unresectabel locally advanced adenocarcinoma of stomach or gastroesophageal junction. Proc ASCO (#1060), 2003.
33. Anthony LB, Vance D, Rubin J, Ajani JA, Stridsberg M. 5-HIAA versus chromogranin A as biochemical marakers in the malignant carcinoid syndrome: results from a randomized multi-institutional clinical trial. Proc ASCO 21:167a (#664), 2002.
34. Dabaja B, Suki D, Bonnen, MD, Ajani JA. Adenocarcinoma of the small bowel: presentation, prognostic factors and outcome of 217 patients. Proc. ASCO 21:164a (#653), 2002.
35. Lazo G, Yao JC, Najam AA, Swisher Sg, Putnam JB, Rothe JA, Mansfield PF, Pisters PW, Ajani JA. Clinical risk factors for peritoneal metastases in esophagogastric junction carcinoma (GEJC). Proc ASCO 21:141a (#526), 2002.
36. Swisher SG, Kelly K, Putnam JB, Ajani JA, Komaki KR, Aggarwal B, Correa AM, Gagneja H, Ho L, Hofstetter W, Kelly JF, Lara A, Liao Z, Lynch PM, Macapinlac HA, Smythe RW, Stevens C, Vaporciyan AA, Walsh GL, Yao JC, Roth JA. Computed Tomography (CT), Endoscopy, Barium Swallow and Positron Emission Tomography (PET) Are Not Predictive of A Complete Pathologic Response Following Preoperative Chemoradiation in Esophageal Cancer Patients. Proceedings Am Assoc Thoracic Surgery, 2002.
37. Phan AT, Najam AA, Yao YC, Mansfield PF, Pisteres PW, Feig BW, Ajani JA. Differences in localization, histology, and pattern of metastasis of gastric cancer among Caucasians, Hispanic, and African-American. Proc ASCO 21:136a (#341), 2002.
38. Moeseyenko V, Van Cutsem E, Tjulanding S, Tchao Y, Sengupta S, Zuber E, Blattmann A, Jacques C, Ajani JA. Docetaxel-cisplatin-5-FU (DCF) versus cisplatin-5-FU (CF) as first line therapy for gastric cancer: interim analyis results on efficacy and safety in multicenter randomized phase III study. Proc ASCO 21:147a (#587), 2002.
39. Shi G, Wang L, Zheng L, Ajani JA, Xie K. Elevated expression of endotheliat nitric oxide synthase correlates with the progression of human gastric adenocarcinoma. Proc. Gastrointestinal Cancer Research:27a, 2002.
40. Zheng L, Le X, Wei D, Wang L, Peng Z, Wu T, Yao J, Ajani JA, Xie K. Expression and regulation of interleukin-8 in human gastric adenocarcinoma. Proc Gastrointestinal Cancer Research:40a, 2002.
41. Alvarez E, Xiong H, Sanchez-Vega B, Vega R, Martin C, Morris J, Hamilton S, Ajani JA, Luthra R. Gene expression analysis of predictive molecular markers in colorectal cancers patients by real time quantitative PCR using RNA from formalin-fixed paraffin embedded tissue. Proc. Gastroinstetinal Cancer Research:15a, 2002.
42. Najam AA, Yao JC, Lenzi R, Carr K, Giacco G, Mansfield PF, Pisters PW, Feig BW, Ajani JA. Linitis plastica is common in women and in poorly differentiated and signet ring cell histologies: an analysis of 217 patients. Proc ASCO 21:166a (#663), 2002.
43. Ebrahimi B, Phan A, Yao JC, Paul MF, Pisters PW, Feig BW, Ajani JA. Phase II clinical trial of Rubitecan against advanced gastric adenocarcinoma. Proc ASCO 21:150a (#596), 2002.
44. Hecht JR, Ajani JA, Michaeli D. Phase II study of G17DT immunogen in combination with cisplatin (CDDP) and 5-fluorouracil (5-FU) in subjects with metastatic or locally recurrent gastric or gastroesophageal cancer previously untreated with chemotherapy for advanced disease. Proc ASCO 21:154a (#613), 2002.
45. Boyer MJ, Boore M, Leichman L, Walpole E, Bjarnason GA, Butts CA, Haller DG, Berlin JD, Hidalgo M, Wilcken N, Stephenson J, Romeyer F, Guld T, Gustafson N, Gallant G, Ajani JA. Phase II study of novel taxane BMS-184476 in previously treated patients with advanced adenocarcinoma involving the stomach or gastroesophageal (GE) junction. Proc ASCO 21:148a (#591), 2002.
46. Ajani JA, Shah MA, Bokemeyer C, Lenz HJ, Burris HA, Van Cutsem E, Usakewicz J, Peeters O, Voi M, Lebwohl D, Safran H. Phase II study of the novel epothilone BMS-247550 in patients (pts) with metastatic gastric adenocarcinoma previously treated with a taxane. Proc ASCO 21:155a (#619), 2002.
47. Baker J, Schnirer II, Yao JC, Carr K, Ho L, Ajani JA. Phase II trial of irinotecan in patients with advanced carcinoid tumor. Proc ASCO 21:166a (#662), 2002.
48. Ukropec J, Pro B, Lozano R, Ajani JA. Refractory CPT-11 induced diarrhea in cancer patients: resolution with octreotide, foru case studies. Proc. ASCO 21:271a (#2904), 2002.
49. Phan A, Nasham N, Yao J, Schnirer I, Najam A, Reddy S, Chang S, Wu T, Ajani JA. Role of phospholipase A2 in the pathogenesi of surgically induced adhensions. Proc. Gastrointestinal Cancer Research:22a, 2002.
50. Liao Z, Cox JD, Jin J, Zhen Z, Ajani JA, Swisher SG, Kelly JD, Stevens C, Roth JA, Vaporciyan AA, Smythe WR, Walsh GL, Putnam JB, Ho L, Allen P, Komaki R. Surgical resection may have increased survival of patients with clinical stage II and III esophageal cancer treated with concurrent chemoradiation. Proceedings American Radium Society, 2002.
51. Wang L, Zheng L, Wei D, Le X, Peng Z, Wu T, Yao J, Ajani JA, Xie K. Unique expression paterns of transcription factor Sp1 and normal and malignant gastric tissues implication of its role in gastric cancer development and progression. Proc. Gastrointestinal Cancer Research:31a, 2002.
52. Ajani JA. Preoperative Approaches Iincluding Preoperative Chemoradiation Therapy in Paitnets with Potentially Resectable Gastric Carcinoma. Proceeding TTD, Alicante, Spain, 12/2001.
53. Ajani JA. Therapy of Advanced Gastric Cancer. Proceedings International Gastric Cancer Symposium. Cairns, Australia, 8/2001.
54. Ajani JA, Ho L, Carr KL, Baker J. Phase II Study of G17DT with Concurrent 5-Fluorouracil and Cisplatin in Patients with Advanced Untreated Gastric Carcinoma. Proceedings Symposium on Gastrin. A key promoter of GI malignancies. Results of immunotherapy trials. San Francisco, 5/2001.
55. Ajani JA. Predicting response to therapy in local-regional gastric carcinoma. Proceedings 4th International Gastric Cancer Congress. New York, 4/2001.
56. Ajani JA, Pro B, Lozano R. Therapeutic Response to Octreotide in Patients with Refractory CPT-11 Induced Diarrhea. Proceedings Treatment of Chemotherapy-induced Diarrhea and Carcinoid Syndrome. New Orleans, 3/2001.
57. Ajani JA, Komaki R, Walsh G, Putnam J, Swisher S, Lahoti S, Ho L, Faust J, Ro J, Smythe R, Vaporcian A, Pisters P, Kelly J, Stevens C, Roth J. CPT-11 Plus Cisplatin as Induction Chemotherapy Followed by Chemoradiotherapy in Resectable Carcinoma of the Esophagus and GE Junction. Proc ASCO 20:131a (#521), 2001.
58. Baker J, Ajani JA, Ho L, Mansfield P, Feig B, Keith M, Charnsangavej C. CPT-11 Plus Cisplatin as Second Line Therapy of Advanced Gastric or GE Junction Adenocarcinoma. Proc ASCO 20:163a (#647), 2001.
59. Xiong Q, Yao JC, Phan A, Giacco G, Hess K, Roth JA, Putnam JB, Walsh GL, Swisher SG, Mansfield PF, Pisters PW, Feig BW, Ajani JA. Frequency of Esophagogastric Junction Involvement Among Upper Gastrointestinal Cancers. Proc ASCO 20:430a (#1718), 2001.
60. Swisher S, Ajani JA, Komaki R, Walsh G, Nesbitt J, Martin F, Lahoti S, Smythe WR, Vaporicyan A, Putnam J, Roth JA. Improved survival in esophageal cancer following taxol based induction chemotherapy, concurrent chemoradiation and surgery. American Association of Thoracic Surgery Abstract, 2001.
61. Swisher S, Wynn P, Mosheim M, Putnam JB, Komaki R, Ajani JA, Smyth WR, Vaporciyan A, Roth J, Walsh G. Is Surgical Resection Indicated for Recurrent Esophageal Tumors Following Definitive Chemoradiation? . American Association of Thoracic Surgery Abstract, 2001.
62. Yao JC, Chiang S, Yu C, Giacco G, Hess K, Carr KL, Mansfield PF, Pisters PW, Feig BW, Ajani JA. The Effects of Gender and Ethnicity on Gastric Cancer Localization. Proc ASCO 20:165a (#658), 2001.
63. Najam AA, Yao JC, Giacco G, Carr KL, Schnirer II, Ajani JA. The Effects of Gender, Race, Histology, and Tumor Location on Patterns of Metastases in Gastric Cancer. Proc ASCO 20:2166a (#661), 2001.
64. Ajani JA. Therapy of Advanced Gastric Carcinoma. Proceedings International Oncology Foundation. On the Internet, 2001.
65. Ajani JA. CPT-11 in GI cancers. Tel Aviv Conference. Israel, 2/2000.
66. Schnirer II, Komaki R, Yao JC, Swisher SG, Putnam J, Pisters PW, Roth JA, Yan M, Janjan N, Mansfield PF, Feig BW, Ajani JA. A Study of Concurrent 5FU/Paclitaxel and Radiotherapy in Patients with Carcinoma of the Upper Gastrointestinal Tract. Proc Asco 19:472a (#1852), 2000.
67. Ajani JA. Chemotherapy of Advanced Gastric Carcinoma. Orlando, 2000.
68. Gopal R, Janjan N, Ajani JA, Ho L, Hamilton S, Cleary K, Dubrow R, Feig B, Pisters P, Lowy A, Mansfield P, Crane C. Comparison of pathologic response among three pre-operative chemoradiation regimens for resectable, locally advanced stomach cancer. Proc ASTRO I J Rad Onc Bio Phy 48(3 Supplement):118 (#15), 2000.
69. Yao JC, Schnirer II, Chiang SS, Kothari A, John R, Cooksley C, Ajani JA. Different Patterns of Gastric Cancer Localization in Men and Women. Proc ASCO 19:652a (#2573), 2000.
70. Mansfield PF, Newman RA, Dougherty T, Ajani JA. Intraperitoneal hyperthermia perfusion using mitomycin. Drug absorption altered by treatment temperature. Proc ASCO, 2000.
71. Swisher SG, Wynn P, Mosheim MP, Putnam JB, Komaki R, Ajani JA, Smythe RW, Vaporciyan AA, Roth JA, Walsh GL. Is Surgical Salvage Indicated for Recurrent Esophageal Tumors Following Definitive Chemoradiation?. Proc Am Assoc Thoracic Surgery, 2000.
72. Ajani JA, Fodor M, Van Cutsem E, Tjulandin S, Moiseyenko V, Cabral F, Majlis A, Chao Y, Zuber E, Blattmann A, Garay C, Jacques C. Multinational Randomized Phase II Trial of Docetaxel and Cisplatin with or without 5-Fluorouracil in Patients with Advanced Gastric or GE Junction Adenocarcinoma. Proc ASCO 19:247a (#957), 2000.
73. Blumenshein G, Ajani JA, Fairweather J, Komaki R, Janjan NA, Ho L, Pisters PW, Walsh GL, Raijman I, Lahoti S, Crane C, Feig BW. Phase I Study of CPT-11 Plus Radiotherapy in Patients with Locally Advanced Upper GI Carcinomas. Proc ASCO 19:322a (#1274), 2000.
74. Macdonald JS, Smalley S, Benedetti J, Estes N, Haller DG, Ajani JA, Gunderson LL, Jessup M, Martenson JA. Postoperative Combined Radiation and Chemotherapy Improves Disease-Free Survival and Overall Survival in Resected Adenocarcinoma of the Stomach and GE Junction. Results of Intergroup Study INT-0116 (SWOG 9008). Proc ASCO 19:1a (#1), 2000.
75. Mansfield PF, Lowy AM, Feig BW, Janjan N, Pisters PW, Rich TA, Ajani JA. Preoperative Chemoradiation for Potentially Resectable Gastric Cancer. Proc ASCO 19:246a (#955), 2000.
76. Ajani JA. Recent Advances in Chemotherapy of Gastric Carcinoma. Taiwan, 2000.
77. Ajani JA. Phase II Study of CPT-11 and Cisplatin in Patients with Advanced Gastric Carcinoma. Proceeding Mount Sainai Chemotherapy Symposium, New York, NY, 11/1999.
78. Ajani JA. New chemotherapy agents and new strategies for local-regional esophageal carcinoma. Proceeding U of Chicago. 1st symposium on Head & Neck and Chest Malignancies, 10/1999.
79. Ajani JA. Combined Modality Approaches to Gastric Gastric Cancer. Proceedings Asian Society of Clinical Oncology. Bali, Indonesia, 8/1999.
80. Ajani JA. An update on systemic chemotherapy and value of chemoradiotherapy for gastric carcinoma. Proceeding 71st meeting of Japanese Gastric Cancer Association, Tokyo, Japan, 6/1999.
81. Crane CH, Janjan NA, Ajani JA, Hunt K, Feig B, Skibber J. Adenocarcinoma of the anus. Is chemoradiotherapy effective?. Proceeding American Radium Society. Big Island, Hawaii, 4/1999.
82. Ajani JA. Preoperative and postoperative approaches to locally advanced gastric carcinoma. Proceeding 3rd International Gastric Cancer Congress, Seoul, Korea, 4/1999.
83. Ajani JA, Hargraves K, Fairweather J. Phase I study of taxol, carboplatin and UFT plus leucovorin in patients with advanced upper GI carcinomas. Proc Fox Chase Cancer Center Symposium, Lanai, Hawaii. 3/1999.
84. Janjan N, Crane CH, Ajani JA, Goswitz M, Hunt K, Feig B, Chapman J, Tich TR, Skibber J, Dong L. 30 Gy is a sufficient dose to control local recurrence from anal cancer. Dosimetric evaluation of N0 patients undergoing chemoradiation. Proc. Radium Society, 1999.
85. Pro B, Ajani JA, Dabaja B, Hargraves K, Fairweather J. A phase I study of Taxol, carboplatin, and UFT plus leucovorin in patients with advanced upper gastrointestinal carcinomas. Proc ASCO, 1999.
86. Fairweather J, Ajani JA, Komaki R, Janjan NA, Pisters P, Walsh GL, Delclos ME, Lynch PM, Raijman I, Feig BW, Hargraves K. Phase I study of CPT-11 plus radiotherapy in paitents with locally advanced upper GI carcinomas. Proc ASCO, 1999.
87. Ajani JA, Fairweather J, Pisters PW, Feig BW, Hargraves K, Charnsangavej C. Phase II study of CPT-11 plus cisplatin in patients with advanced gastric and GE junction carcinomas. Proc ASCO, 1999.
88. Dabaja B, Ajani JA, Pro B, Abi-Said D, Nasr F, Cooksley C, Campos LT. Small bowel adenocarcinoma: 20-year M. D. Anderson Cancer Center esperience. Proc ASCO, 1999.
89. Medessey. Small cell lung. Asco, 1999.
90. Ajani JA. Current status of chemotherapy of colorectal carcinoma. Proc. Radiology Society of North America, 12/1998.
91. Ajani JA. Preoperative approaches and preoperative chemoradiation therapy in patients with potentially resectable gastric carcinoma. Proceedings Fifth Annual International Conference on Gastrointestinal Oncology. Bordeaux, France, 9/1998.
92. Ajani JA. Gastric Cancer. Tokyo. Japan proceedings on Comprehensive Conference on Gastric Carcinoma, 4/1998.
93. Lynch P, Raijman I, Pazdur, Delclos M, Martin F, Roth J. three-step taxol-based therapy in patients with resectable esophageal carcinoma. Proceedings, Investigators of Taxol Workshop. St. Thomas, Virgin Island, 3/1998.
94. Raijman I, Siddique I, Skibber J, Ajani JA, Lahoti S, Lynch P. Palliation of malignant colorectal strictures with expandable metallic stents: Experience with 20 patients. Proceeding DDW, 1998.
95. Raijman I, Siddique I, Ajani JA, Evans D, Abbruzzese J, Lahoti S, Lynch P. Palliation of malignant gastric outlet and duodenal obstruction using expandable metallic stents. Proceedings DDW, 1998.
96. Anthony L, Ajani JA, Schimer S, Venook A, Bukowsky R, Pommier R, Saltz L, Dandona P, Rubin J. Phase IV open-label long-term trial of the safety, tolerability, and efficacy of octreotide acetate LAR injected at 4-week intervals in malignant carcinoid syndrome. Proc ASCO 17:268a, 1998.
97. Nesbitt J, Ajani JA, Komaki R, Walsh G, Putnam J, Swisher S, Pisters P, Lynch P, Raijman I, Pazdur R, Delclos M, Matine F, Roth J. Preoperative taxol-based chemotherapy followed by chemoradiation therapy in patients with potentially resectable esophageal carcinoma. Proc ASCO 17:282a (#1086), 1998.
98. Ajani JA, Mansfield PF, Janjan N, Pisters P, Lynch P, Raijman I, Pazdur R, Goswitz M, Feig B, Hargraves K, Myerson R, Gunderson L. Properative chemoradiation therapy in patients with potentially resectable gastric carcinoma. Proceeding ASCO 17:283a (#1089), 1998.
99. Ajani JA. Hepatic arterial chemotherapy is investigational for patients with liver metastases from colorectal carcinoma. Proceedings 8th International Conference. Regional Cancer Treatment September 1997. Ulm, Germany:Supplement, page: 71, 10/1997.
100. Wallace S, Yang D, Li C, Ajani JA, Chuang VP, Lawrence D, Richli W, Carrasco CH. Polymer drug delivery system. Proceedings 8th International Conference. Regional Cancer Treatment September 1997. Ulm, Germany:Supplement, page: 4, 10/1997.
101. Ajani JA. Paclitaxel studies in GI malignancies at M. D. Anderson Cancer Center using a variety of schedules. Proc Taxol Workshop. Atlanta, GA, 4/1997.
102. Ajani JA. Paclitaxel in the treatment of gastric and esophageal carcinomas. Bristol-Myers Proc Investigators Meeting, Puerto Rico, 3/1997.
103. Ajani J, Fiarweather J, Dumas P, Pazdur R, Mansfield PF. A phase II study of Taxol in patients with advanced untreated gastric carcinoma. Proc ASCO, 1997.
104. Kelsen DP, Ginsberg R, Qian C, Gunderson L, Mortimer J, Estes N, Haller D, Ajani JA, Kocha W, Roth J, Minsky B. Chemotherapy followed by operation versus operation alone in the treatment of patients with localized esophageal cancer. A preliminary report of intergroup study 113 (RTOG 89-11). Proc ASCO 16:276a (#982), 1997.
105. Raijman I, Siddique I, Ajani JA. How much luminal dilatation (if any) is necessary prior to palcement of an esophageal wallstent?. Proc ASGE, 1997.
106. Swisher S, Hu M, Holmes EC, Hunt K, Ajani J, McFadden D, Nelson S, Nesbitt J, Putnam JB, Vaporcian A, Walsh G, Zinner M, Roth J. Impact of number of involved lymph nodes on long-term survival in esophageal cancer. Proceeding SSO, 1997.
107. Raijman I, Siddique I, Ajani JA, Lynch P. Large experience in a cancer center in the palliation of malignant dysphagia and fistulae with the wallstent. Proc ASGE, 1997.
108. Raijman I, Siddique I, Ajani JA, Lynch P. Management of a rectovesical malignant fistula with the coated wallstent. Proc ASGE, 1997.
109. Anthony L, Ajani JA, Schirmer W, Venook A, Bukowski R, Pommier R, Saltz L, Dandona P, Rubin J. Octreotide acetate long acting release (OALAR): 5-HIAA response in a randomized multi-center double-blind trial in carcinoid syndrome. Proceedings 79th Annual Meeting of the Endocrine Society, 1997.
110. Pazdur R, Patt Y, Ajani JA, Dumas P, Sonnichsen D, Ferreira I, Birkhofer M. Phase II/pharmacology study of UFT (BMS-200604) and leucovorin in refractory colorectal cancer patients. Proc ASCO 16:959a, 1997.
111. Rubin J, Ajani JA, Schirmer W, Venook A, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Results of a randomized study of the safety, tolerability, and efficacy of multiple double-blind dose levels of octreotide acetate LAR given subcutaneous Sandostatin in malignant. Proc ASCO 16:A997, 1997.
112. Raijman I, Siddique I, Ajani JA, Lynch P. The palliation of malignant dysphagi with chemoradiation therapy does not increase the rate of potentially fatal complications from coated wallstent. Proc ASGE, 1997.
113. Raijman I, Siddique I, Ajani JA, Lynch P. Tumor factors that may affect the outcome after palliation with the esophageal wallstent. Proc ASGE, 1997.
114. Feig BW, Lowy AM, JanJan N, Ajani JA, Charnsangavej C, Rich TA, Mansfield PF. Alteration of nodal staging by preoperative chemoradiotherapy for potentially resectable gastric cancer. Proceedings WHO conference on Gastric Cancer. Athens, Greece, 12/1996.
115. Ajani JA. Multidisciplinary Approaches to Carcinoma of the Stomach and Esophagus. Proceedings International Symposium on Gastroenterology. Shanghai, China, 11/1996.
116. Ajani JA. Current status of chemotherapy of advanced gastric carcinoma. Proceeding WHO-CC for Gastric Cancer (12th International Seminar. 6Th General Assembly). Seoul, Korea:108-109, 9/1996.
117. Ajani JA. Pharmacokinetics, dosing, schedule, toxicity and activity of Taxol. Oncology Symposium (Bristol-Myers Oncology). Istanbul, Turkey, 9/1996.
118. Ajani JA. Medical therapy of resected and advanced colorectal carcinoma. Proc Sixth International Congress on Anti-Cancer Treatments. Paris, France, 2/1996.
119. Lowy AM, Feig BW, JanJan N, Ajani JA, Rich TA, Mansfield PF. A pilot study of preoperative chemoradiation for potentially resectable gastric cancer. Proc SSO, 1996.
120. Ajani JA, Mansfield P, Dumas P, Pazdur R, Evans D, Curley S, Pisters P, Lynch P, Ota D. All chemotherapy preoperatively with cisplatin, 5-FU, Intron in patients with potentially resectable gastric carcinoma. Proc ASCO 15:208 (#474), 1996.
121. Ajani JA. Current therapeutic approaches in patients with potentially resectable gastric carcinoma. Proc. Symposium on GI Malignancies. Zaragosa, Spain, 1996.
122. Mansfield PF, Dougherty T, Ajani JA, Madden T, Newman RA. Intraperitoneal hyperthermic perfusion using mitomycin C: effect of temperature on systemic drug absorption. Proc ASCO 15:473 (#1497), 1996.
123. Ajani JA. New agents and combined modality therapy for carcinoma of the esophagus. Proceeding International Symposium on Thoracic Malignancies. Pittsburgh, Pennsylvania, 1996.
124. Rivera E Ajani JA. New chemotherapy regimen with doxorubicin, streptozotocin, and 5-fluorouracil for patients with metastatic islet cell carcinoma. Porc ASCO 15:232 (#568), 1996.
125. Duanabdudiy E, Ajani JA, Yang D, Chuang V, Brown C, Carrasco C, Lawrence D, Wallace S. Phase I-II evaluation of vascular embolization with microencapsulated cisplatin (C-HAE) in neuroendocrine tumors (NET) metastatic to the liver. Proc. ASCO, 1996.
126. Diamandidou E, Ajani JA, Yang D, Chuang V, Brown C, Carrasco C, Lawrence D, Wallace S. Phase I-II study of vascular embolization with microencapsulated cisplatin in neuroendocrine tumors metastatic to the liver. Proc ASCO 15:192 (#410), 1996.
127. Ajani JA. Carcinoma of the esophagus. (Extended abstract). Chilean Socienty of Internal Medicine. Santiago, Chile, 10/1995.
128. Ajani JA. Carcinoma of the Stomach. (Extended abstract). Chilean Socienty of Internal Medicine. Santiago, Chile, 10/1995.
129. Ajani JA. Carcinomas of the Colon and Rectum. (Extended abstract). Chilean Socienty of Internal Medicine. Santiago, Chile, 10/1995.
130. Ajani JA. Combined modality therapy of carcinoma of the esophagus and stomach. Proc Combined Modality Therapy in the 21st Century organized by Rowell Park Cancer Institute held in Buffalo, NY, 10/1995.
131. Ajani JA, Ilson D, Kelsen D. Therapy of carcinoma of the esophagus with Taxol. Proceedings ECCO, Paris, France, 10/1995.
132. Ajani JA. Therapy of carcinoma of the esophagus. Operate or not to operate. Proceeding Europeon School of Oncology Course. Milano, Italy, 9/1995.
133. Mansfield PF, Dougherty T, Ajani JA. A prospective study of thermal distribution during intraperitoneal hyperthermic perfusion. Proc. SSO, 1995.
134. Ajani JA. Approaches to patients with resectable gastric carcinoma. First International Gastric Conference. Kyoto, Japan, 1995.
135. Lynch PM, Jeon HM, Howard L, Ajani J, Levin B, Frazier M. Common hMSH2 mutation in unrelated families with variable family history of colorectal cancer. Proc. AGA, 1995.
136. Lowy J, Ajani JA, Mansfield PF. Peritoneal staging of patients with resectable gastric carcinoma. Proc SSO, 1995.
137. Pazdur R, ERivera, Diaz-Canton E, Lassere Y, Bready B, Ajani JA. Phase I trial of UFT (uracil:tegafur) with leucovorin: 14-day schedule. Proc ASCO 14:482 (#1578), 1995.
138. Pazdur R, Diaz-Canton E, Meyers C, Abbruzzese J, Patt Y, Rivera E, Touroutoglou N, Edwards K, Bready B, Ajani JA. Phase II trial of CI-980 in metastatic colorectal carcinoma patients. ASCO 14:208 (#511), 1995.
139. Lowy AM, Leach PF, Mansfield D, Ota D, Pazdur R, Dumas P, Ajani JA. Repsonse to neoadjuvant chemotherapy predicts outcome in resectable gastric cancer. ASCO 14:211 (#523), 1995.
140. Pazdur R, Bready B, Diaz-Canton E, Gray R, Belt R, Goodwin W, Dakhil SR, Fueger R, Winn R, Ajani JA. Sequential modulation of fluorouracil with leucovorin, PALA, and alpha-interferon: Phase II trial in advanced colorectal carcinoma. Proc ASCO 14:208 (#510), 1995.
141. Ajani JA, Ilson D, Bhalla K, Forastiere A, Pazdur R, Martin R, Daugherty K, Kelsen DP. Taxol, cisplatin, 5-FU: A multi-institutional phase II study in patients with carcinoma of the esophagus. ASCO 14:203 (#489), 1995.
142. Ajani JA. New agents in the treatment of advanced upper gastrointestinal cancers. Proceedings 5th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies. Salzburg, Austria, 3/1994.
143. Ajani JA, Ilson D, Daugherty K, Pazdur R, Kelsen DP. Phase II trial of paclitaxel (Taxol) in patient with carcinoma of the esophagus. Proceedings Taxol Symposia in Madrid, Spain and Rome, Italy, 3/1994.
144. Sugarman SM, Pazdur R, Brown C, Vosika GJ, Jones DV, Markowitz A, Ajani JA, Bready B, Soo E, Levin B. A phase II trial of Immther for previously untreated patients with metastatic colorectal cancer to the liver. Proc ASCO, 1994.
145. Sugarman SM, Ajani JA, Daugherty K, Winn R, Lanzotti V, Bearden JD, Abbruzzese JL. A phase II trial of tototecan for the treatment of advanced measurable colorectal cancer. Proc ASCO, 1994.
146. Ajani JA, Ilson D, Daugherty K, Pazdur R, Kelsen DP. Paclitaxel (Taxol) is active against carcinoma of the esophagus. Report of a phase II trial. Proceeding ASCO 13:192 (#555), 1994.
147. Ajani JA. Paclitaxel in therapy of esophageal and head & neck carcinomas. Taxol Symposia in Beijing, China, 1994.
148. Lowy AM, Ajani JA, Mansfield PF. Peritoneal cytologic staging in gastric adenocarcinoma. Proc ASCO, 1994.
149. Pazdur R, Lassere Y, Bready B, Rhodes V, Soo E, Ajani JA, Abbruzzese JL, Patt Y, Sugarman S, Levin B. Phase II clinical trial of UFT plus oral folinic acid: A potentially effective oral treatment regimen for metastatic colorectal carcinoma. Proc 8th EORTC Symposium, 1994.
150. Pazdur R, Lassere Y, Bready B, Soo E, Ajani JA, Sugarman S, Patt Y, Abbruzzese JL, Raber MN. Phase II trial of docetaxel in metastatic colorectal carcinoma. Proc 8th EORTC Symposium, 1994.
151. Rich T, Skibber J, Ota D, Ajani JA, Buchholz D, Cleary K, Dubrow R, Levin B, Lynch P, Meterssian S, Pearce A, Roubein R. Pre-operative radiotherapy plus 5-FU continuous infusion in highly proliferative tumors. Proc ASTRO, 1994.
152. Pazdur R, Rhodes V, Lassere Y, Bready B, Soo E, Ajani JA, Abbruzzese JL, Sugarman S, Jones D, Markowitz A, Patt Y, Ho D, Levin B. UFT plus leucovorin. A potentially effective oral regimen in colorectal carcinoma. Proc ASCO, 1994.
153. Ajani JA, Mayer R, Ota D, Steele G, Evans D, Roh M, Sugarbaker J, Dumas P, Gray C, Vena D, Stablein D. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. Proceedings Fourth International congress on Anti-Cancer Chemotherapy; Paris, France, 2/1993.
154. Ajani JA. Approaches to therapy of potentially resectable gastric carcinoma. Proc Sixth Advances in Oncology Symposium, Mexico City, 1993.
155. Ajani JA. Chemotherjapy of metastatic gastric carcinoma. Proc Sixth Advances in Oncology Symposium, Mexico City, 1993.
156. Kelsen DP, Ajani JA, Ilson DH. Clinical activity of Taxol in patients with adenocarcinoma and squamous carcinoma of the esopha;gus and gastroesophageal junction: A preliminary report. Proc. ECCO, Jarusalem, 1993.
157. Ajani JA, Dumas P, Pazdur R, Mansfield P, Ota D. Phase II trial of oral etoposide in untreated patients with advanced gastric carcinoma. Proc ASCO 12:217a (#217), 1993.
158. Weinstein GD, Rich TA, Shumate CR, Skibber JM, Ajani JA, Ota DM. Preoperative chemoradiation and complete surgical excision with or without intraoperatative electron beam boost (EB-IORT) for advanced primary rectal cancer. Proc ASTRO, 1993.
159. Ajani JA, Grossie VB, Ota D, Nishioka K. Clinical Experience with alpha-difluoromethyl ornithine in advanced colon carcinoma and its pharmacology. International Symposium on Polyamine in Cancer; Montgomery, Texas, 11/1992.
160. Ajani JA, Roth JA, Ota DM. Current therapy of upper gastrointestinal carcinomas. Proc 10th Congress on Future Directions in Chemotherapy, Geneva, Switzerland, 3/1992.
161. Ajani JA. Approaches to therapy of potentially resectable gastric carcinoma. Proc. International Conference on Biology and Treatment of Gastrointestinal Malignancies. Frankfurt, Germany, 2/1992.
162. Rich TA, Ota DM, Skibber JM, Schumate CR, Morrison WH, Ajani JA, Levin B, Cleary K, Roubein L. Preoperative radiotherapy and 5-FU concomitant infusion for low rectal adenocarcinoma. Proc. International Conference on Biology and Treatment of Gastrointestinal Malignancies. Frankfurt, Germany 407, 2/1992.
163. Ajani JA. Systemic chemotherapy for potentially resectable adenocarcinoma of the esophagus and gastroesophageal junction. Proc. International Conference on Biology and Treatment of Gastrointestinal Malignancies. Frankfurt, Germany, 2/1992.
164. Ajani JA, Roth J, Putnam B, Ryan B, Walsh G, Lynch P, Gould P. Feasibility of five preoperative chemotherapy courses for resectable adenocarcinoma of the esophagus and GE junction. Proc AACR 33:218 (#1306), 1992.
165. Kim Y, Ajani JA, El-Naggar A, Roth J, Lynch P, Ota D. Potentially resectable upper gastrointestinal adenocarcinomas: Evaluation of prognostic factors. Proc ASCO 11:181 (#538), 1992.
166. Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, Sugarbaker DJ, Dumas P, Gray C, Vena D, Stablein D. Preoperative and postoperative chemotherapy (CT) for patients with potentially resectable gastric carcinoma (PRGC). Proc ASCO 11:165 (#476), 1992.
167. Rich TA, Ota DM, Skibber JM, Schumate CR, Morrison WH, Ajani JA, Levin B, Cleary KR, Roubein LD. Preoperative radiotherapy and 5-FU concomitant infusion for low rectal adenocarcinoma. Proc Am Soc Surg Oncol, 1992.
168. Rich TA, Terry NA, Meistrich ML, Brown BW, Cleary KR, Ajani JA, Ota DM, Peters LJ. Tumor cell kinetics of human rectal cancer: Relationship between potential doubling time, response to irradiation and chemotherapy, and patterns of failure. Proc ASTRO, 1992.
169. Grossie B, Ajani JA, Ota D, Nishioka K. Tumor growth recovery after BCNU treatment is delayed by difluoromethylornithine (DFMO). Proc AACR 33 (#2517), 1992.
170. Evans D, Byrd R, Rich T, Ajani JA, Ames F. Preoperative chemoradiotherapy and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Proc. Southwester Surgical Society, 4/1991.
171. Ajani JA, Ota D, Jessup J, Ames F, Faintuch J, Jackson D. Pilot study of pre- and postoperative chemotherapy for resectable gastric carcinoma. Proc Third International Congress on Neo-Adjuvant Chemotherapy. Paris, France, 2/1991.
172. Abbruzzese J, Pazdur R, Ajani JA, Daugherty K, Tarassoff P, Levin B. A phase II trial of gemcitabine in patients with advanced colorectal cancer. Proc ASCO (#A456), 1991.
173. Shumate CR, Rich TA, Hohn DC, Ajani JA, Ota DM. Advanced rectal cancer. Improved tumor response with preoperative chemotherapy and radiotherapy. Proc SSO, 1991.
174. Ajani JA, Roth J, Ryan B, Putnam J, Pazdur R, Faintuch J, Dumas P, Levin B, McMurtrey M, Gutterman J. High-dose chemotherapy with GM-CSF for resectable adenocarcinoma of the esophagus. Proc ASCO 10 (#A472), 1991.
175. Gomez J, Pazdur R, Ajani JA, Winn R, Abbruzzese JL, Patt YZ, Pilat S, Levin B. Phase II study of 5-fluorouracil and recombinant alpha-2A interferon in the treatment of advanced gastric carcinoma. Proc ASCO 10 (#A454), 1991.
176. Derderian P, Pazdur R, Ajani JA, Winn R, Abbruzzese JL, Patt YZ, Pilat S, Levin B. Phase II study of 5-fluorouracil and recombinant alpha-2A interferon in the treatment of advanced pancreatic carcinoma. Proc ASCO 10 (#A453), 1991.
177. Jaiyesimi I, Pazdur R, Patt YZ, Ajani JA, Abbruzzese JL, Daugherty K, Levin B. Phase II study of recombinant interferon alpha 2A and continuous infusion 5-fluorouracil for metastatatic colorectal carcinoma. Proc ASCO 10 (#A455), 1991.
178. Linke K, Pazdur R, Ajani JA, Abbruzzese J, Patt Y, Levin B. Phase II trial of amonafide in advanced pancreatic carcinoma. Proc ASCO 10 (#A452), 1991.
179. Rich T, Ames F, Roh M, Ajani JA. Post-operative irradiation (XRT) and protracted 5-fluorouracil infusion for biliary tract cancers. Proc ASCO 10 (#A498), 1991.
180. Meistrich ML, Terry NHA, Rich TA, White RA, Brown BW, Ota DM, Ajani JA, Cleary KR, Peters LJ. Potential doubling times of human rectal carcinomas and treatment response. Proc International Society for Analytic Cytology (ISAC), 1991.
181. Rich T, Meistrich M, Terry N, White A, Peters L, Cleary K, Ajani JA, Ota D. Pre-treatment tumor cell kinetics in patients with advanced primary and recurrent rectal adenocarcinomas are associated with treatment response to pre-operative chemoradiotherapy. Proc 9th International Congress of Radiation Research, 1991.
182. Roth J Ajani JA. Multidisciplinary therapy for esophageal cancer. Proc UICC, Hamburg, W. Geramany, 8/1990.
183. Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Proceeding of University of Maryland Symposium: Recent Advances in Etoposide Therapy. Alexandria, Virginia, 5/1990.
184. Rich TA, Ajani JA, Ellerbroek NA, Ota DM, Hohn DC, Levin B. Low dose continuous infusion 5-fluorouracil (5-FU) with or without cisplatin (CDDP) during external beam radiotherapy (XRT) for adenocarcinomas of the gastrointestinal (GI) tract. Proc Third International Conference on Interaction of Radiation and Systemic Therapy, Monteray, California, 3/1990.
185. Ellerbroek, NA, Fossella FV, Rich TA, Ajani JA, Komaki R, Roth JA, Holoye PY. Low-dose continuous infusion cisplatinum combined with external beam irradiation for advanced colorectal adenocarcinoma and for unresectable non-small cell lung carcinoma. Proc The Third International Conference on the Interaction of Radiation Therapy and Systemic Therapy, Monteray, CA, 3/1990.
186. Ajani JA, Roth JA. Pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus. Proc 6th International Conference on the Adjuvant Therapy of Cancer. Tucson, Arizona, 3/1990.
187. Ajani JA, Ota DM, Jackson DE. Resectable gastric carcinoma (RGC). Pre- and postoperative chemotherapy. Proc 6th International Conference on the Adjuvant Therapy of Cancer. Tucson, Arizona, 3/1990.
188. Ajani JA Jackson DE. Therapeutic approaches to locoregional and metastatic carcinoma of the stomach. Symposium: Recent Advances in Etoposide Therapy. Proc Future Trends in Chemotherapy. Geneva, Switzerland, 3/1990.
189. Ajani JA, CCarrasco, DJackson, NSamaan, DLawrence, SWallace. Biochemical response to SMS-201-995 given prior to chemoembolization for neuroendocrine tumors. Proc AACR 31:185, 1990.
190. Nishioka K, Ajani JA, Ota DM, Grossie VB, Patenia T, Rotriguez T, Wagle JR. Clinical and experimental studies of DFMO on human colorectal carcinoma. Proc 1990 International Symposium on Polyamines in Molecular and Medical Biology:84-85, 1990.
191. Grossie B, Nishioka K, Ajani JA, Ota D. Control of TPN-enhanced tumor growth by substituting ornithine for arginine. J Parent Enter Nutrition 14, 1990.
192. Baker FL, Sanger LJ, Spitzer G, Ajani JA, Brock WA. Drug sensitivitiy of normal and malignant tissue in vitro. Proc AACR, 1990.
193. Grossie VB, Thompson CW, Nishioka K, Ajani JA, Ota DM. Enhanced antitumor activity of difluoromethylornithine (DFMO) when administered with essential amino acid-based TPN. J Parent Enter Nutrition 14:105, 1990.
194. Ajani JA, Roth J, Ryan B, Putnam W, Pazdur R, Faintuch J, Jackson D, Rodriguez A, Levin B, DeCaro L, McMurtrey M, Gutterman J. Feasibility and toxicities of GM-CSF given with high-dose chemotherapy for resectable adenocarcinoma of the esophagus. Proc ASCO 9:118, 1990.
195. Robey-Cafferty S, Ajani JA, Ota D, Roth J, Bruner et al. P-glycoprotein in patients with upper gastrointestinal tumors. Proc Society of Pathology, 1990.
196. Gressot L, Pazdur R, Markowitz A, Abbruzzese J, Faintuch J, Patt Y, Ajani JA, Edwards C, Levin B, Gutterman J. Phase I-II studies of recombinant interleukin-2 and 5-flurouracil plus folinic acid for patients with advanced colorectal carcinoma. Proc ASCO 9:118, 1990.
197. Pazdur R, Abbruzzese J, Faintuch J, Ajani JA, Patt Y, Jackson D, Markowitz A, Winn R, Gutterman J, Levin B. Phase II study of recombinant interferon-alpha (rIFN) and 5-Fluorouracil (5-FU) in patients (pts) with advanced colorectal carcinoma. Proc ASCO 9:117, 1990.
198. Dhingra K, Talpaz M, Dhingra HM, Ajani JA, Rothberg J, Gutterman JU. Recombinant alpha interferon (Roferon) and weekly cisplatinum (CDDP) combination therapy. A phase I trial. Proc ASCO 9:193, 1990.
199. Grossie B, Ota D, Ajani JA, Nishioka K. Reduction of difluoromethylornithine-induced thrombocytopenia with ornithine. J Cell Biochem 14c(suppl):97, 1990.
200. Ajani JA, Ota D, Ames F, Jackson D, Boddie A, Abbruzzese J, Hohn D, Roh M, Faintuch J, Levin B, Jessup J. Pre- and postoperative chemotherapy for operable gastric carcinoma. Proc Sixteenth International Congress of Chemotherapy. Jerusalem, Israel, 6/1989.
201. Ajani JA, Carrasco C, Charnsangavej C, BLevin, SWallance. Systemic and regional therapy of neuroendocrine tumors of the gastrointestinal tract. Proc IV International conference on Advances in Regional Cancer Therapy. Berchtesgaden, West Germany, 6/1989.
202. Faintuch JS, Ajani JA, Abbruzzese J, Edwards C, Raber M. Combination chemotherapy of metastatic carcinoma of unknown primary with etoposide, cisplatin, and 5-fluorouracil. Phase II study. Proc ASCO 8:123 (#479), 1989.
203. Rich TA, Ajani JA, Abbruzzesse J, Ames F, Roh M, Hohn D. Combined modality therapy for cancer of the biliary tract. Proceeding Gilbert Fletcher Society Meeting, 1989.
204. Baker FL, Spitzer G, Ajani JA, Brock WA, Sanger LJ, Wike J. Enrichment of tumor stem cells by short term high density (STHD) incubation in the adhesive tumor cell culture system (ATCCS). Proc AACR 30:606 (#2413), 1989.
205. Perez-soler R, Khokhar AR, Lautersztain J, Ajani JA, Dexeus F, Raber M, Lopez-Berenstein G. Phase I clinical and pharmacology study of liposome entrapped cis-bis-neodecanoato trans-R,R-1,2 diamino cyclohexane platinum (II) (L-NDDP). Proc ASCO 8:67 (#259), 1989.
206. Perez-soler R, Khokhar AR, Lautersztain J, Ajani JA, Dexeus F, Raber M, Lopez-Berenstein G. Phase I clinical and pharmacology study of liposome entrapped cis-bis-neodecanoato trans-R,R-1,2 diamino cyclohexane platinum (II) (L-NDDP). Proc EORTC, 1989.
207. Abbruzzese J, Ajani JA, Faintuch J, Patt Y, Pazdur R, Blaustein A, Braud E, Edwards C, Levin B. Phase II study of iproplatin (CHIP) in patients with advanced gastric and pancreatic carcinomas. Proc ASCO 8:123 (#477), 1989.
208. Roth JA, Ajani JA, McMurtrey M, Ryan B, Natarajan G, Rodriguez A, Levin B, Faintuch J. Pilot study of pre- and postoperative combination chemotherapy for resectable adenocarcinoma of the esophagus. Proc International Conference on Diseases of the Esophagus, Chicago, 1989.
209. Ajani JA, McMurtrey M, Ryan B, DeCaro L, Rich T, Abbruzzese J, Jackson D, Rodriguez A, Faintuch J, Levin B, Mountain C, Roth J. Pre- and postoperative chemotherapy for operable adenocarcinoma of the esophagus. Proc ASCO 8:121 (#471), 1989.
210. Ajani JA, Kavanagh J, Patt Y, Levin B, Edwards C, Gutterman J. Roferon and doxorubicin combination active against advanced islet cell or carcinoid tumors. Proc AACR 30:293 (#1165), 1989.
211. Nishioka K, Ota DM, Grossie VB, Abbruzzese JL, Levin B, Ajani JA. Clinical and pharmacological effects of continuous infusion of DFMO in patients with advanced colorectal carcinoma. Proc 1988 Internat Symposium on Polyamines in Biochemical and Clinical Research. Sorrento, Naples (Italy). (#P115), 6/1988.
212. Grossie VB, Ota DM, Ajani JA, Nishioka K. Selective elimination of DFMO-induced thrombocytopenia by ornithine in tumor-bearing rats. Proc 1988 Internat Symposium on Polyamines in Biochemical and Clinical Research. Sorrento, Naples (Italy). (#P108), 6/1988.
213. Ajani JA, MMcMurtrey, Rich T, Roth J, Blackburn R, DeCaro L, Faintuch J, Levin B, Ryan B, Mountain C. Prolonged chemotherapy (CT) of locally advanced squamous carcinoma of the esophagus (SCCE). Proc 2nd Internat Congress on Neo-Adjuvant Chemotherapy; Paris, France, 2/1988.
214. Ajani JA, Baker F, Tueni E, Spitzer G. Activity and patterns of corss sensitivity of recombinant alpha interferon against primary human tumors in vitro. Proc AACR 29:492 (#1957), 1988.
215. Roubein L Ajani JA. Brain metastases in patients with colorectal carcinoma. Proc ASGE, 1988.
216. Grossie B, Ota D, Nishioka, Ajani JA. Control of TPN-enhanced tumor-growth with polyamine-directed chemotherapy. Proc ASPEN, 1988.
217. Patt Y, Lamki L, Jessup J, Levin B, Ajani JA, Halverson C, Schweighardt S, Shanken J, Murray L. Detection of occult metastases adenocarcinoma in patients with rising serum CEA by 111-In labeled monoclonal anti-CEA ZCE-025. Proc AACR 29:425 (#1693), 1988.
218. Ajani JA, Ota D, Grossie B, Abbruzzese J, Faintuch J, Levin B, Goudeau P, Nishioka K. Difluoromethylornithine in patients with advanced colorectal carcinoma: Toxicity, response, pharmacology, and polyamine levels. Proc AACR 29:201 (#799), 1988.
219. Tueni E, Spitzer G, Ajani JA, Baker F, Fan D. In vitro chemosensitivity of fresh lung tumors in the adhesive tumor-cell culture system (ATCCS) vs lung tumor cell lines in the tetrazolium assay (MTT): Implications for drug screening. Proc AACR 29:487 (#1937), 1988.
220. Baker F, Ajani JA, Spitzer G, Brock W. Mechanism of action of alpha interferon. Proc AACR 29:414 (#1647), 1988.
221. Grossie B, Ota D, Ajani JA, Nishioka K. Modulation of difluoromethylornithine toxicity by concomitant ornithine treatment in tumor-bearing rats. Proc AACR 29:346 (#1375), 1988.
222. Spitzer G, Baker F, Ajani JA. Patterns of pleiotropic drug resistance of primary human lung tumors in vitro. Proc AACR 29:316 (#1257), 1988.
223. Weeks A, Abbruzzese J, Raber M, Gravel D, Ajani JA, Levin B, Grem J, Chun H. Phase I study of MeCCNU given in combination with 5-FU plus high-dose folinic acid in patients with metastatic colorectal carcinoma. Proc AACR 29:203 (#806), 1988.
224. Ajani JA, Abbruzzese J, Blackburn R, Faintuch J, Boman B, Levin B. Phase II evaluation of trimetrexate in patients with advanced colorectal carcinoma. Proc ASCO 7:115 (#442), 1988.
225. Abbruzzese J, Ajani JA, Blackburn R, Faintuch J, Patt Y, Levin B. Phase II study of didemnin-B in advanced colorectal cancer. Proc AACR 29:203 (#805), 1988.
226. Grossie B, Nishioka K, Medley R, Ajani JA, Ota DM. Role of arginine in total parenteral nutrition (TPN)-enhanced tumor growth in the rat. Proc FASEB, 1988.
227. Baker F, Spitzer G, Ajani JA, Brock W. ATCCS. Assay of primary human tumor cells for drug sensitivity using the adhesive-tumor-cell culture system (ATCCS). Proceedings of Prediction of Tumor Treatment Response, Banff, Canada (#C-7), 1987.
228. Faintuch JS, Abbruzzese J, Ajani JA, Raber M, Goudeau P, Frost P, Levin B. Combination chemotherapy of metastatic carcinoma of unknown primary origin with etoposide (VP-16), cisplatin (CDDP), and 5-fluorouracil (5-FU): A preliminary report. Proc ASCO 6:130 (#508), 1987.
229. Rios A, Levin B, Ajani JA, Abbruzzese J, Faintuch J, Ende K. Combination of recombinant human interferon gamma (rIFNgamma) and 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma (CRC). Proc ASCO 6:84 (#328), 1987.
230. Ajani JA, McMurtrey M, Rich T, Blackburn R, Chang-Tung E, Faintuch J, Levin B, Mountain C. Combined modality therapy with effective prolonged systemic component for locally advanced squamous cell carcinoma of the esophagus (SCE). Proc ASCO 6:82 (#320), 1987.
231. Fan D, Baker F, khokhar AR, Spitzer G, Tomasovic B, Ajani JA, Newman RA, Finders M, Joe T, Brock WA. Comparison of cisplatinum and its analogs at equivalent in vitro doses in a primary adhesive human tumor cell culture assay (ATCCS). Proc AACR 28:421 (#1667), 1987.
232. Grossie VB, Ota DM, Ajani JA, Nishioka K. Differential effects of difluoromethylornithine (DFMO) on hepatic and tumor polyamine metabolism in sarcoma-bearing rats. Proc AACR 28:319 (#1264), 1987.
233. Ajani JA, Baker F, Spitzer G, Kelly A, Tomasovic B, Fan D, Brock W. Differential in vitro activity of biologics and chemotherapy drugs compared in human tumors. Proc 15th International Congress of Chemotherapy, Instanbul, Turkey, 1987.
234. Baker F, Ajani JA, Spitzer G, Brock W. Evidence for cell cycle retardation of human tumors by recombinant alpha interferon (IFNRA) in vitro. Proc Second Conference on Immunity to Cancer; Williamsburg, Virginia:26 (#C-6), 1987.
235. Baker FL, Tomasovic B, Spitzer G, Ajani JA, Williams M, Finders M, Tofilon P, Brock WA. High colony forming efficiency (CFE) of primary human tumor cells cultured in the adhesive-tumor-cell culture system (ATCCS). Proc AACR 28:28 (#112), 1987.
236. Rich TA, Ajani JA, Goudeau P, Ende K. High dose radiotherapy (XRT) with protracted venous 5-fluorouracil (PV 5FU) radiosensitization for advanced gastrointestinal cancer. Proc ASCO 6:79 (#309), 1987.
237. Spitzer G, Ajani JA, Baker F, Brock W, Fan D, Tomasovic B. In vitro comparison of antitumor efficacy of investigational and standard drugs at the equitoxic concentrations in the adhesive tumor cell culture system (ATCCS): An in vitro method of drug screening. Proceedings of Prediction of Tumor Treatment Response, Banff (#C-5), 1987.
238. Ajani JA, Baker F, Brock W, Spitzer G, Kelly A, Tomasovic B, Fan D. In vitro comparison of radiation therapy (RT) and chemotherapy (CT) response in primary human tumors. Proc AACR 28:447 (#1774), 1987.
239. Ajani JA, Baker F, Kelly A, Spitzer G, Brock W, Tomasovic B, Joe T, Fan D. In vitro drug response of primary human tumor cells in the adhesive tumor culture system (ATCCS) predicts for clinical response. Proceedings Conference on Prediction of Tumor Treatment Response, Banff, Canada (#C-6), 1987.
240. Smith E, Ajani JA, Blackburn R, Rich T, Roth J, Levin B. Oral nutrition support of patients with esophageal cancer. Proc Am Dietetic Assoc, 1987.
241. Nishioka K, Grossie VB, Ota DM, Ajani JA. Polyamine directed preferential nutritional repletion of normal tissues in tumor-bearing hosts. Proc AACR 28:317 (#1257), 1987.
242. Ajani JA, Baker F, Spitzer. Relationship of antitumor response between recombinant gamma interferon (IFNRG) and cytotoxic drugs against human tumors in vitro. Proc Second Conference on Immunity to Cancer; Williamsburg, Virginia:38 (#D-16), 1987.
243. Carrasco CH, Ajani JA, Samaan NA, Charnsangavej C, Boman B, Wallace S. Sequential hepatic artery embolization (HAE) for metastatic islet cell carcinoma. Proc ASCO 6:83 (#322), 1987.
244. Ota D, Grossie B, Ajani JA, Chang T, Patenia D, Goudeau, Nishioka K. Toxicity and erythrocyte (RBC) polyamine levels of cancer patients receiving continuous i.v. difluoromethylornithine (DFMO). Proc AACR 28:230 (#913), 1987.
245. Baker F, Spitzer G, Ajani JA, Fan D, Tomasovic B, Finders M, Brock W. Application of the adhesive-tumor-cell culture (ATCCS) in the testing of chemotherapy drugs. Proc Texas Anticancer Drug Development Consortium, Topatio Springs, Boerne, Texas, 11/1986.
246. Wallace S, Carrasco CH, Charnsangavej C, Ajani JA, Samaan NA. Embolization of neuroendocrine metastases. Proceedings of Current Approaches for the Diagnosis and Treatment of Gastrointestinal Cancer. Houston, Texas:38, 11/1986.
247. Wallace S, Carrasco CH, Charnsangavej C, Ajani JA, Samaan NA. Hepatic artery embolization in the carcinoid syndrome. proceeding of Gastrointestinal Endocrine Tumors. Houston, Texas, 11/1986.
248. Ajani JA, McMurtrey MJ, Rich TA, Levin B, Mountain CF. Role of chemotherapy in squamous cell carcinoma of the esophagus. Proceedings of Current Approaches for the Diagnosis and Treatment of Gastrointestinal Cancer. Houston, Texas:26, 11/1986.
249. Nishioka K, Grossie VB, Ota DM, Ajani JA, Harris WB, Chang T, Patenia D. Effect of total parentaral nutrition and intravenous infusion of DFMO on polyamine metabolism in tumor-bearing hosts. Proc International Conference on Polyamines in Life Sciences, Japan, 7/1986.
250. Ajani JA, Baker F, Spitzer G, Brock W, Thielvoldt D, Tomasovic B, McMurtrey, Plager C. Adhesive tumor-cell culture system (ATCCS): Preliminary results of clinical correlations. Proc AACR 27:411 (#1631), 1986.
251. Ajani JA, Levin B, Goudeau P, Kanojia M, Faintuch J, Boman B. Adriamycin with sequential methotrexate and 5-fluorouracil (AMF) for advanced gastric cancer. Proc ASCO 5:93 (#364), 1986.
252. Grossie VB, Ota DM, Stephens LC, Ajani JA, Nishioka K. Antitumor activity of host toxicity of continuous intravenous (IV) alpha-difluoromethylornithine (DFMO). Proc AACR 27:292 (#1160), 1986.
253. Chawla SP, Benjamin RS, Hortobagyi GN, Ajani JA, Bodey GP. Decreased cardiotoxicity of 96-hr continuous infusion Adriamycin compared with Epirubicin. Proc ASCO 5:44 (#172), 1986.
254. Baker F, Brock W, Spitzer G, Ajani JA, Tomasovic B, Williams M, Boch S. Design consideration of an in-vitro drug and radiation sensitivity assay for human tumor cells. Proc AACR 27:411 (#1634), 1986.
255. Ajani JA, Tomasovic B, Spitzer G, Kavanagh J, Thielvoldt, Baker F, Gershenson D. In-vitro activity of 2-fluoro-ara AMP against gynecologic malignancies in the soft agar assay. Proc 14th International Cancer Congress, Budapest, Hungry 1:407 (#1560), 1986.
256. Spitzer G, Ajani JA, Baker F, Thielvoldt D, Tomasovic B. In-vitro comparison of response to interferon and chemotherapy of human tumors. Proc AACR 27:313 (#1243), 1986.
257. Reichardt P, Baker F, Ajani JA, Spitzer G, Tomasovic B. In-vitro drug combinations for human tumor cells in the adhesive tumor-cell culture system (ATCCS). 14th International Cancer Congress, Budapest, Hungry 3:1073 (#4124), 1986.
258. Reichardt P, Baker F, Ajani JA, Spitzer G, Tomasovic B, Nelson R. In-vitro drug combinations for human tumor cells in the adhesive tumor-cell culture system (ATCCS). Proc AACR 27:371 (#1474), 1986.
259. Singletary E, Baker F, Thielvoldt D, Spitzer G, Ajani JA, Tomasovic B, Benjamin R, Ames F. Influence of prior chemotherapy (PT) on in-vitro drug response in melanoma and sarcoma. Proc ASCO 5:128 (#500), 1986.
260. Grossie B, Benitez M, Ota D, Ajani JA, Nishioka K. Influence of total parenteral nutrition (TPN) on tumor growth and erythrocyte (RBC) polyamine levels of colon tumor-bearing (TB) rats. Proceeding ASPEN, 1986.
261. Grossie B, Nishioka K, Ota D, Ajani JA. Influence of TPN on polyamine biosynthesis in tumor bearing (TB) rats. JPEN 10:3S, 1986.
262. Boman B, Gagen M, Ajani JA, Dimery IW, Bonnen E, Golando J, Neidhart J. Phase I study of Schering recombinant gamma interferon. Proc ASCO 5:236 (#923), 1986.
263. Spitzer G, Baker F, Ajani JA, Tomasovic B, Thielvoldt D. Activity of investigational agents: Caracemide(CA), Taxol (TA), and Spirogermanium (SP) in the adhesive tumor cell culture system. Proceedings AACR 26:334 (#1316), 1985.
264. Baker F, Spitzer G, Ajani JA, Lukeman J, Pathak S, Brock W, Tomasovic B, Thielvoldt D. Adhesive tumor cell culture system: Successful primary culture of human tumor cells on an adhesive substrate. Proceedings AACR 26:367 (#1450), 1985.
265. Grossie B, Nishioka K, Martin S, Ajani JA, Ota D. Amino acid (AA) precursors of erythrocyte (RBC) polyamines in tumor bearing rats. Proceedings JPEN 9(1):117, 1985.
266. Patt Y, Ajani JA, Boddie A, Charnsangavej C, Claghorn L,Soski M. Arterial cisplatin (CDDP) and floxuridine (FUDR) for colorectal cancer metastases to liver. Recent Advances in Cancer, Proceedings 14th International Congress of Chemotherapy, Kyoto (University of Tokyo Press), Japan:1168-1167, 1985.
267. Patt Y, Boddie A, Ajani JA, Charnsangavej C, Claghorn L, Soski M, Mavligit G. Arterial cisplatin (CDDP) and floxuridine (FUDR) for colorectal cancer metastatic (CRC) to the liver. Proceedings ASCO 4:94 (#C-366), 1985.
268. Ajani JA, Baker FL, Spitzer G, Mountain C, Tomasovic B, Thielvoldt D. Chemosensitivity of lung cancer according to the stage: An assessment in the adhesive tumor cell culture system (ATCCS). Proceedings ASCO 4:179 (#C-699), 1985.
269. Singletary E, Romsdahl M, Spitzer G, Baker F, Ajani JA, Tomasovic B, Thielvoldt D. Epidermal growth factor (EGF) induced proliferation and increased chemosensitivity with hormonal interactions in the human stem cell assay (HTSCA) and in the newly developed adhesive human tumor culture system. Proceedings AACR 26:200 (#790), 1985.
270. Patt YZ, Boddie A, Charnsangavej C, Ajani JA, Soski M, Claghorn L, Mavligit GM. Hepatic arterial cisplatin and FUDR for colorectal cancer in the liver. Proceedings 2nd International Conference on Advances in Regional Cancer Therapy, Giessen, W. Germany (#26), 1985.
271. Boddie AW, Patt YZ, McBride CM, Wallace S, Ajani JA, Charnsangavej C, Soski M, Levin B. MDAH experience with implantable Infusaid pumps and Medtronic drug administration devices. Proceedings 2nd International Conference on Advances in Regional Cancer Therapy, Giessen, W. Germany (#5), 1985.
272. Harris W, Ota D, Grossie B, Ajani JA, Nishioka K. Monitoring difluoromethyl ornithine (DFMO) inhibition and tumor polyamine.(PA) synthesis. Proceedings AACR 26:374 (#1474), 1985.
273. Ajani JA, Carrasco C, Charnsangavej C, McClure R, Patt Y, Benjamin R, Samaan N, Wallace S. Regional therapy of endocrine tumors metastatic to the liver. Proceedings 2nd International Conference on Advances in Regional Cancer Therapy. Giessen, W. Germany (#92), 1985.
274. Umbach GE, Tomasovic B, Spitzer G, Umbach U, Merchant N, Ajani JA, Hug V. Chemosensitivity testing of human malignancy at drug concentrations based on dose survival curves of bone marrow progenitor cells. Proceedings AACR 25:373 (#1480), 1984.
275. Harris WB, Grossie VB, Ota DM, Nishioka K, Ajani JA, Chang T. Effect of continuous infusion difluoromethyl ornithine (DFMO) in tumor bearing rats receiving total parenteral nutrition (TPN). Proceedings AAS, 1984.
276. Ajani JA, Wallace S, Charnsangavej C, Carrasco CH. Percutaneous portal vein chemotherapy infusion for metastatic colorectal carcinoma. Proceedings Intra-arterial and Intra-cavitary Chemotherapy. San Diego (#16), 1984.
277. Ajani JA, Kantarjian H, Kanojia M, Karlin D. Phase II trial of cis-platinum in advanced upper gastrointestinal cancer. Proceedings ASCO 3:147 (#C-573), 1984.
278. Ajani JA, Baker FL, Spitzer G, Tomasovic B, Umbach GThielvoldt D. Relative in vitro activity of chemotherapy agents on colony forming cells from human tumors and normal bone marrow. Proceedings International symposium on Myelosuppressive Effects of Antineoplastic Drugs, Miami, Florida (#8), 1984.
279. Hairston DL Ajani JA. Therapy of carcinoma of the appendix. Proceedings ASCO 3:142 (#C-554), 1984.
280. Harris W, Ajani JA, Hickey R, Stroehlein J. Therapy of islet cell tumors: A review of the M.D. Anderson experience. Proceedings ASCO 3:146 (#C-570), 1984.
281. Stein SH, Ajani JA, Karlin DA, Nelson RS. Combination chemotherapy of hepatocellular carcinoma with 5-fluorouracil, Adriamycin, mitomycin-C, and methyl CCNU (FAMMe). Proceedings ASCO 2:120 (#C-470), 1983.
282. Ajani JA, Legha SS, Karlin DA, Hill CS. Combination chemotherapy of metastatic carcinoid tumors with 5-FU, Adriamycin, and cytoxan (FAC) and 5-FU, Adriamycin, mitomycin-C, and methyl CCNU (FAMMe). Proceedings ASCO 2:124 (#C-486), 1983.
283. Kanojia MD, Ajani JA, Barlogie B, Zander A. Combination chemotherapy of metastatic colorectal carcinoma with vinblastine, bleomycin, and cis-platinum (VBP). Proceedings ASCO 2:124 (#C-485), 1983.
284. Mahajan SL, Ajani JA, Kanojia MH, Vellekoop L, Bodey GP. Comparison of tow schedules of sequential high methotrexate (MTX) and 5-fluorouracil (5-FU) for metastatic colorectal carcinoma. Proceedings ASCO 2:122 (#C-476), 1983.
285. Feun LG, Yap BS, Benjamin RS, Savaraj N, Burgess MA, Ajani JA, McKelvey E, Bodey GP. Phase I trial of 1,4,5,6,8-pentazacenaphylene, 3-amino, 1,5-dihydro-5-methyl-1-B-D-ribofuranosyl-5'-phosphate ester (TCN-P, NSC 280594) on a 5-day continuous infusion schedule. Proceedings AACR 24:144 (#C-568), 1983.
286. Ranginani RR, Ajani JA, Bedikian AY, Mckelvey EM, Bodey GP. Sequential conventional dose methotrexate (MTX) and 5-fluorouracil (5-FU) in the primary therapy of metastatic colorectal carcinoma. Proceedings ASCO 2:122 (#C-476), 1983.
287. Ajani JA, Legha SS, Burgess MA, Bodey GP. Phase I study of spirogermanium given for 5 consecutive days per week. Proceedings ASCO 1:16 (#C-64), 1982.

Book Chapters

1. Phan A, Ajani JA. Chemoradiotherapy of Gastric, Esophageal, Pancreatic, and Biliary Carcinomas., 2002.
2. Ajani JA. Multimodality therapy of local-regional gastric carcinoma. In: Book of Japanese Gastric Cancer Surgical Society. Tokyo, Japan. June, 1999.
3. Ajani JA. Adjuvant therapy of colon and rectal carcinoma. In: Progress in Anti-Cancer Chemotherapy. Blackwill Science, 135-142, 1997.
4. Ajani JA. Current approaches to local-regional gastric carcinoma. In: Polish Society of Gastric Carcioma, 1997.
5. Ajani JA. Current therapy of advanced gastric carcinoma. In: Polish Society of Gastric Carcioma, 1997.
6. Touroutoglou N, Arcenas AG, Ajani JA. Biology and Therapy of neuroendocrine tumors of the gastrointestinal tract. RPR, 285-298, 1996.
7. Philip PA, Ajani JA. Carcinoma of the Esophagus. In: Medical Oncology: A Comprehensive Review. RPR, 225-234, 1996.
8. Nishioka K, Mitchell MF, Ajani JA. Clinical studies of polyamines and their anti-metabolite. In: Polyamines in Cancer: Basic Mechanisms and Clinical Approaches. Chapman and Hall Publishing Company, 251-278, 1996.
9. Philip PA, Ajani JA. Gastric Carcinoma. In: Medical Oncology: A Comprehensive Review. RPR, 235-246, 1996.
10. Ajani JA, Kelsen DP, Rich TA, Roth JA. Chemotherapy and radiation therapy for squamous cell carcinoma and adenocarcinoma of the esophagus and gastroesophageal junction. In: Thoracic Oncology. W. B. Saunders Company, 433-441, 1995.
11. Arcenas AG, Ajani JA, Carrasco CH, Levin B, Wallace S. Vascular occlusive therapy of pancreatic endocrine tumor metastatic to the liver. In: Frontiers of Gastrointestinal Research, Endrocrine Tumors of the Pancreas-Recent Advances. Karger, 1994.
12. Ajani JA Rich TA. Combination of chemotherapy and radiotherapy in the treatment of colorectal carcinomas. In: Chemoradiation Therapy of Gastrointestinal Tract. Lea & Febiger, 330-336, 1993.
13. Soh LT, Ajani JA. Gastric carcinoma. In: Medical Oncology: A Comprehensive Review. RPR, 175-184, 1993.
14. Soh LT, Ajani JA. Pancreatic carcinoma. In: Medical Oncology: A Comprehensive Review. RPR, 163-174, 1993.
15. Arcenas AG, Ajani JA. Pancreatic Islet Cell and Carcinoid Tumors. In: Medical Oncology: A Comprehensive Review. RPR, 185-198, 1993.
16. Rich TA Ajani JA. Radiotherapy plus concomitant chemotherapy for cancers of the stomach, pancreas, and biliary system. In: Chemoradiation Therapy of Gastrointestinal Tract. Lea & Febiger, 303-314, 1993.
17. Rich TA, Ajani JA. Chemoradiation therapy for Rectal cancer. In: Combined Modality Cancer Therapy. Radiation and Infusional Chemotherapy. Precept Press, 151-162, 1991.
18. Rich TA, Ajani JA. Chemoradiotherapy approaches for treatment of loco-regional bile duct carcinoma. In: Combined Modality Cancer Therapy. Radiation and Infusional Chemotherapy. Precept Press, 135-142, 1991.
19. Rich TA, Ajani JA. Chemoradiotherapy approaches for treatment of loco-regional pancreatic carcinoma. In: Combined Modality Cancer Therapy. Radiation and Infusional Chemotherapy. Precept Press, 143-1150, 1991.
20. Rich TA, Ochran T, Boyer A, Ames F, Ota D, Evans D, Ajani JA. Electron bean intraoperative radiotherapy at M. D. Anderson Cancer Center: Preliminary results. In: Intraoperative Radiation Therapy. Paragamon Press, 81-83, 1991.
21. Roth JA, Ajani JA, Rich TA. Multidisciplinary therapy for esophageal cancer. In: Advances in Surgery. 23. Year Book Medical Publishers, 239-260, 1990.
22. Ajani JA, Roth JA, Ryan B, McMurtrey M, Rich TA. Resectable Adenocarcinoma of the Esophagus:A Study of Pre- and Postoperative Chemotherapy. In: Adjuvant Therapy of Cancer VI. W.B. Saunders, 396-404, 1990.
23. Hall JT, Wallace S, Carrasco CH, Charnsangavej C, Richli W, Ajani JA, Samaan N, Dodd GD. Gastrointestinal and pancreatic endocrine tumors. In: FL Chan and C Wang. Vol 3, No. 1; May. Baillere Tindall, 121-152, 1989.
24. Ajani JA, Levin B, Wallace S. Systemic and regional therapy of advanced islet cell tumors. In: Gastrointestinal Endocrinology, The Gastroenterology Clinics of North America. 18(4). W. B. Saunders, 923-930, 1989.
25. Ajani JA, McMurtrey M, Rich TA, Blackburn R, Chang-Tung E, Levin B, Roth J A, Mountain CF. Carcinoma of the esophagus: Contribution of chemotherapy. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 272-281, 1988.
26. Baker FL, Spitzer G, Ajani JA, Brock WA. Drug and radiation sensitivity testing of primary human tumor cells using the adhesive-tumor-cell culture system. In: Prediction of Response to Chemotherapy. Alan R. Liss, Inc, 1988.
27. Wallace S, Carrasco C, Ajani J, Charnsangvej C, Samaan N. Embolization of neuroendocrine hepatic metastases. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 337-349, 1988.
28. Rich TA Ajani JA. Radiotherapy of esophageal carcinoma. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 261-271, 1988.
29. Ajani JA Samaan NA. Carcinoids and Islet Cell Neoplasms. (Selected abstracts) . In: ONCOLOGY OVERVIEW NCI/ICRDB, December, 1987.
30. Nishioka K, Grossie VB, Ota DM, Ajani JA. Changes in polyamine metabolism in tumor-bearing hosts with total parenteral nutrition and intravenous infusion of alpha-difluoromethylornithine. In: The Physiology of Polyamines. CRC Press Inc, 1987.
31. Bodey GP Ajani JA. Chemotherapeutic and hormonal approaches to treatment of carcinoma of the pancreas. In: Surgical Diseases of the Pancreas. Lea and Febiger, 748-761, 1987.
32. Ajani JA. Diagnosis and treatment of esophageal carcinoma (selected abstracts). In: ONCOLOGY OVERVIEW NCI/ICRDB, June, 1987.
33. Stroehlein JR Ajani JA. Gastric carcinoma. In: Current Therapy in Gastrointestinal and Liver Diseases. B. C. Decker, Inc, 120-123, 1986.
34. Patt Y, Ajani JA, Boddie A, Charnsangavej C, Claghorn L, Soski M. Arterial cisplatin and floxuridine for colorectal cancer metastatic to the liver. In: Recent Advances in Chemotherapy. University of Tokyo Press, 1166-1167, 1985.
35. Umbach GE, Spitzer G, Ajani JA, Thames H, Hug V, Rudolph F, Drewinko B. Factors determining methotrexate cytotoxicity in human bone marrow progenitor cells: Implications for in vitro drug testing of human tumors. In: Cloning of Human Tumor Stem Cells. Grune and Stratton, 443-450, 1984.
36. Spitzer G, Baker F, Umbach G, Hug V, Tomasovic B, Ajani JA, Haynes M, Sahu SK. Growth factor enhancement of the in vitro stem cell assay. In: Predictive Test in Human Cancer; Recent Results in Cancer Research. Springer-Verlag, 1984.
37. Ajani JA, Spitzer G, Baker F, Umbach GE, Tomasovic B, Sahu SK. Human tumor cloning assay with prospective clinical correlations and association between in vitro sensitivity and the number of drugs tested. In: Cloning of Human Tumor Stem Cells. Grune and Stratton, 595-604, 1984.
38. Spitzer G, Singletary E, Tomasovic B, Umbach G, Merchant N, Hug V, Ajani JA. Human tumor cloning culture supplements. In: Cloning of Human Tumor Stem Cells. Grune and Stratton, 215-228, 1984.

Letters to the Editor

1. Ajani JA, Blum MA, Welsh J, Hofstetter WL, Swisher SG. Celebrate or Calibrate? We Say Calibrate. J Clin Oncol 29(19):2732, 7/1/2011. e-Pub 5/23/2011. PMID: 21606421.
2. Ajani JA. Reply to D. Vordermark. J Clin Oncol. e-Pub 5/2009. PMID: 19414659.
3. Hofstetter W, Ajani J, Swisher SG. Author reply. Cancer 109:1449, 2/2007. PMID: 17328056.
4. Ajani JA. Operate on my stomach cancer? Oh, no--not you, or not yet! J Clin Oncol 22(9):1763-4; author reply 1764-5, 5/2004. PMID: 15118003.
5. Vauthey JN, Ajani JA. Liver transplantation and hepatocellular carcinoma biology: beginning of the end of the era of educated guesses. J Clin Oncol 21(23):4265-7, 12/2003. PMID: 14581443.
6. Ajani JA. It's the poison that killed him, you say! J Clin Oncol 21(20):3885, 10/2003. PMID: 14551310.
7. Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 18(23):4001-3, 12/2000. PMID: 11099333.
8. Ajani JA. In rectal carcinoma, colostomy or no colostomy: is this the question? J Clin Oncol 11(1):193-4, 1993. PMID: 8418233.
9. Rich TA, Hughes L, Ajani JA, Brock W. Low dose, continuous infusion 5-fluorouracil plus radiotherapy for anal cancer. Int J Radiat Oncol Biol Phys 18(3):710, 3/1990. PMID: 2318708.
10. Ajani JA. Bolus fluorouracil for metastatic colorectal carcinoma? J Clin Oncol 7(9):1366-7, 9/1989. PMID: 2769332.

Grant & Contract Support

Title: Inhibition of Hedgehog Signaling in Gli-1 + Adeno CA of the Esoph or GE Junction.
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/1/2013 - 6/30/2018
 
Title: Dual pathway inhibition in biomarker enriched patients with advanced GE cancer.
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2013 - 3/31/2018
 
Title: Esophagus SPORE: Biology of Barrett’s Esophagus and Adenocarcinoma. Translational Medicine
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 12/1/2012 - 11/30/2017
 
Title: A Phase 3, Randomized, Double-Blinded Study
Funding Source: Imclone
Role: Principal Investigator
Duration: 6/26/2012 - 6/25/2013
 
Title: Genotypying and Phenotyping of Diffuse Gastric Cancer
Funding Source: Taiho Pharma USA
Role: Principal Investigator
Duration: 11/18/2011 - 11/17/2015
 
Title: A Phase I, Open-Label, Multicenter, Dose Escalation, Multidose Study
Funding Source: Bristol-Myers Squibb
Role: Principal Investigator
Duration: 9/23/2011 - 9/30/2013
 
Title: An Open-label, single-center, Phase 1 / 2 Study
Funding Source: Novartis
Role: Principal Investigator
Duration: 8/15/2011 - 11/30/2013
 
Title: TAIHO U.S. CONSULTANT AGREEMENT in conjunction with 2010-0590
Funding Source: Taiho Pharma USA
Role: Principal Investigator
Duration: 1/25/2011 - 1/31/2015
 
Title: An Open-Label, Multicenter Randomized, Phase 3 Study
Funding Source: Taiho Pharma USA
Role: Principal Investigator
Duration: 1/11/2011 - 1/31/2016
 
Title: Genetic and functional alterations of the c-MET RTK in cancer progression
Funding Source: Amgern Inc.
Role: Principal Investigator
Duration: 11/29/2010 - 11/29/2014
 
Title: Development and Validation of Prognostic Model for Gastric Center.
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Lee
Duration: 4/1/2010 - 3/31/2015
 
Title: Prediction of Pathologic Complete Response by Gene Expression Profiling in Esophageal Cancer.
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2/1/2010 - 1/31/2015
 
Title: Prediction of pathologic complete response by gene expression profiling in esophageal cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2/1/2010 - 1/31/2015
 
Title: A Phase Ib/II Study
Funding Source: Mebio Pharm Co. Ltd
Role: Principal Investigator
Duration: 10/27/2009 - 4/30/2013
 
Title: A Phase II Open-Label Study
Funding Source: ACT Biotech, Inc
Role: Principal Investigator
Duration: 7/21/2009 - 7/31/2012
 
Title: A randomized, double-blind, multi-center phase III study
Funding Source: Novartis Pharm.
Role: Principal Investigator
Duration: 6/23/2009 - 12/31/2012
 
Title: Genetic Instability & Risk for Esophageal Carcinoma
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Xifeng Wu, M.D., Ph.D.
Duration: 3/1/2008 - 1/31/2013
 
Title: An Oxaliplatin-based Phase II correlative randomized study
Funding Source: Sanofi-Synthelabo Inc.
Role: Principal Investigator
Duration: 11/1/2004 - 12/31/2012
 
Title: Cancer Center Support Grant (PP-MRP0)
Funding Source: NIH/NCI
Role: Co-Program Leader
Duration: 9/4/1998 - 6/30/2013

Last updated: 8/1/2013